Gerhard Ehninger

Q: What Schools Are Affiliated With Gerhard Ehninger

Gerhard Ehninger is affiliated with the following schools: Humboldt University of Berlin, University of Freiburg, University of Marburg, Ludwig Maximilian University of Munich, University of Nantes, Hannover Medical School, University of Hamburg, University of Tübingen, Technical University of Munich, University of Münster, Children's University, TU Dresden

Gerhard Ehninger's AcademicInfluence.com Rankings

Gerhard Ehninger

Philosophy

#4826

World Rank

#7479

Historical Rank

Logic

#2203

World Rank

#3142

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Gerhard Ehninger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gerhard Ehninger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (2002) (1721)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro (2004) (1277)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
Acute myeloid leukaemia (2016) (802)
Peripheral-blood stem cells versus bone marrow from unrelated donors. (2012) (698)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006) (693)
Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. (1995) (477)
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. (2010) (464)
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. (2007) (416)
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial (2011) (336)
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate (2004) (328)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (2004) (327)
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. (1997) (316)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. (2015) (314)
Rapamycin extends murine lifespan but has limited effects on aging. (2013) (313)
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. (2013) (299)
Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer (2004) (296)
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. (2014) (296)
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium (2009) (293)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. (2006) (282)
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes (2010) (280)
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection (1999) (273)
Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study (2012) (270)
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. (2014) (269)
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. (2003) (264)
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. (2002) (257)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia (2012) (256)
Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. (2009) (247)
Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. (1998) (238)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia (2014) (235)
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. (2012) (229)
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation (2017) (228)
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers (2001) (222)
Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. (2011) (219)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). (2020) (219)
Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing (2014) (215)
Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma (2001) (213)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). (2012) (211)
Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro (2010) (207)
Prevalence and prognostic impact of NPM 1 mutations in 1485 adult patients with acute myeloid leukemia ( AML ) (2006) (207)
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. (2004) (205)
The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany (2000) (205)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. (2003) (197)
Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. (1999) (188)
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. (2018) (188)
The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. (2013) (187)
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. (2009) (186)
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. (2001) (183)
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem-cell transplantation. (2007) (182)
CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. (2013) (181)
BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. (2006) (177)
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts (2016) (172)
Second HLA-identical sibling transplants for leukemia recurrence. (1992) (169)
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma (2004) (168)
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia (2016) (166)
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. (2010) (163)
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. (1991) (163)
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia (2005) (161)
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 (2004) (159)
Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia (2003) (158)
Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants (2000) (150)
Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease (1991) (148)
Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. (2008) (147)
Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. (1991) (147)
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor (2003) (146)
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. (2009) (142)
Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. (2015) (141)
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia (2009) (140)
Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. (1988) (137)
How I treat hyperleukocytosis in acute myeloid leukemia. (2015) (135)
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. (2009) (134)
Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. (2012) (133)
Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies (2002) (129)
HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. (2014) (128)
Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. (2001) (127)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry (2016) (125)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. (2007) (123)
Estimation of high-resolution HLA-A, -B, -C, -DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. (2009) (122)
Spleen enlargement in healthy donors during G–CSF mobilization of PBPCs (2001) (122)
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). (2008) (122)
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. (2001) (119)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia (2011) (118)
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). (2005) (118)
Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. (2001) (117)
Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. (2004) (110)
Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. (1999) (110)
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. (2006) (110)
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease (2002) (108)
Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. (1993) (108)
Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation (2009) (108)
Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. (1993) (106)
What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? (1997) (106)
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. (2000) (105)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial (2018) (103)
Gene and haplotype frequencies for the loci hLA-A, hLA-B, and hLA-DR based on over 13,000 german blood donors. (2003) (102)
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia (2003) (100)
Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? (1994) (99)
FLT3 Mutations in Early T-Cell Precursor ALL Characterize a Stem Cell Like Leukemia and Imply the Clinical Use of Tyrosine Kinase Inhibitors (2013) (98)
Inhibition of platelet‐derived growth factor receptorβ by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro (2007) (98)
18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia (2011) (94)
Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori-associated gastritis. (1999) (92)
Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. (2011) (91)
Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. (2010) (90)
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR” (2017) (89)
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. (1999) (88)
Allogeneic hematopoietic SCT for patients with autoimmune diseases (2009) (88)
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin (2000) (87)
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study (2010) (87)
Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. (2003) (86)
Gene‐Expression Profiling of CD34+ Hematopoietic Cells Expanded in a Collagen I Matrix (2006) (85)
The Graft Content of Donor T Cells Expressing γδTCR+ and CD4+foxp3+ Predicts the Risk of Acute Graft versus Host Disease after Transplantation of Allogeneic Peripheral Blood Stem Cells from Unrelated Donors (2007) (85)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study (2013) (83)
Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. (2009) (83)
Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. (2009) (81)
Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells (2012) (81)
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia (2004) (80)
Epigenetic alterations in longevity regulators, reduced life span, and exacerbated aging-related pathology in old father offspring mice (2018) (79)
Plasma vitamin E and beta-carotene concentrations during radiochemotherapy preceding bone marrow transplantation. (1990) (79)
Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. (2012) (79)
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. (2014) (78)
Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urine (2007) (78)
Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival (2009) (78)
Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors (2012) (77)
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. (2012) (76)
Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome (2000) (76)
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells (2006) (75)
Evaluation of STR informativity for chimerism testing – comparative analysis of 27 STR systems in 203 matched related donor recipient pairs (2004) (75)
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. (2012) (75)
Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7 (2017) (75)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse (2018) (75)
TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation (2016) (74)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. (2016) (74)
A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform (2017) (74)
Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Patients with AML. (2004) (73)
Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. (1996) (73)
MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. (2008) (73)
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide (2013) (73)
A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia (2014) (72)
TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY: A Multicenter Phase III Study (1995) (72)
Polarization of human hematopoietic progenitors during contact with multipotent mesenchymal stromal cells: effects on proliferation and clonogenicity. (2006) (71)
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis (2007) (71)
Every-other-day feeding extends lifespan but fails to delay many symptoms of aging in mice (2017) (70)
Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia (2001) (70)
Respiratory failure in patients undergoing allogeneic hematopoietic SCT—a randomized trial on early non-invasive ventilation based on standard care hematology wards (2012) (68)
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse (2011) (68)
Cytokine‐Driven Differentiation of Blasts from Patients with Acute Myelogenous and Lymphoblastic Leukemia into Dendritic Cells (2000) (68)
MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation (2012) (68)
Defining Optimum Conditions for the Ex Vivo Expansion of Human Umbilical Cord Blood Cells. Influences of Progenitor Enrichment, Interference with Feeder Layers, Early‐Acting Cytokines and Agitation of Culture Vessels (1999) (68)
Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. (2015) (67)
Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. (2001) (67)
Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells (2013) (67)
Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. (2002) (66)
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. (2013) (66)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial (2012) (65)
Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. (1993) (65)
Eradication of Helicobacter pylori and stability of remissions in low-grade gastric B-cell lymphomas of the mucosa-associated lymphoid tissue: results of an ongoing multicenter trial. (2000) (65)
Strategies and Clinical Implications of Chimerism Diagnostics after Allogeneic Hematopoietic Stem Cell Transplantation (2004) (65)
Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways (2010) (65)
Karyotype complexity and prognosis in acute myeloid leukemia (2016) (63)
Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. (2013) (62)
High-resolution HLA haplotype frequencies of stem cell donors in Germany with foreign parentage: how can they be used to improve unrelated donor searches? (2013) (62)
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. (2005) (62)
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia (2008) (62)
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia (2016) (62)
Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (2003) (62)
Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. (1995) (61)
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function (2010) (60)
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients (2010) (60)
Ongoing somatic mutations and clonal expansions after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. (1998) (60)
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system (2014) (60)
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation (2017) (59)
Leptin mediates a proliferative response in human gastric mucosa cells with functional receptor. (2001) (59)
Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients (2008) (59)
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? (2020) (58)
Incidence of local CMV infection and acute intestinal GVHD in marrow transplant recipients with severe diarrhoea. (1994) (58)
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. (2004) (58)
Activation of the RAS Pathway Is Predictive for a Chemosensitive Phenotype of Acute Myelogenous Leukemia Blasts (2005) (58)
Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12 (2007) (57)
Oxygen tension plays a critical role in the hematopoietic microenvironment in vitro (2012) (57)
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia (2007) (57)
Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. (2005) (57)
Underestimation of inversion (16) in acute myeloid leukaemia using standard cytogenetics as compared with polymerase chain reaction: results of a prospective investigation (1997) (56)
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. (2012) (56)
Immunophenotyping is an independent factor for risk stratification in AML (2003) (56)
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT (2018) (55)
Sorafenib Versus Placebo in Addition to Standard Therapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial (2014) (55)
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. (2013) (55)
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia (2006) (54)
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. (2012) (54)
Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. (2008) (54)
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML) (2003) (53)
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. (2019) (53)
Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping (2006) (52)
High-resolution human leukocyte antigen allele and haplotype frequencies of the Polish population based on 20,653 stem cell donors. (2011) (52)
Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. (2013) (52)
Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies (2012) (52)
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia (2006) (52)
RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. (2015) (52)
Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. (2007) (52)
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival (2009) (51)
Locally advanced small-bowel adenocarcinoma missed primarily by capsule endoscopy but diagnosed by push enteroscopy. (2003) (51)
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. (2018) (51)
Helicobacter pylori vacA, iceA, and cagA status and pattern of gastritis in patients with malignant and benign gastroduodenal disease (2001) (50)
Thalidomide: Rationale for Renewed Use in Immunological Disorders (1995) (50)
The pharmacokinetics and metabolism of mitoxantrone in man (2004) (50)
Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation (2012) (50)
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). (2001) (50)
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment (2003) (50)
Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow (2003) (50)
Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML. (2021) (49)
Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. (2018) (49)
New strategies for prophylactic platelet transfusion in patients with hematologic diseases. (2001) (49)
Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. (2009) (49)
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape (2017) (49)
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid (2004) (49)
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells (2010) (48)
Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. (2002) (48)
The clinical mutatome of core binding factor leukemia (2020) (48)
Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial (2010) (48)
HIGH FREQUENCY OF GRAFT‐VERSUS‐HOST‐LIKE SYNDROMES FOLLOWING SYNGENEIC BONE MARROW TRANSPLANTATION (1988) (48)
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. (2007) (48)
Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation (1998) (48)
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia (2016) (47)
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study (2006) (47)
Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. (2007) (47)
Membranous nephropathy after bone marrow transplantation in ciclosporin treatment. (1989) (47)
Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. (2007) (46)
Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. (2000) (46)
Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy (2017) (46)
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. (2004) (46)
Fast Appearance of Donor Dendritic Cells in Human Skin: Dynamics of Skin and Blood Dendritic Cells after Allogeneic Hematopoietic Cell Transplantation (2006) (46)
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. (2016) (46)
Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. (2011) (45)
BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells. (2008) (45)
Evidence for oxidative activation of mitoxantrone in human, pig, and rat. (1991) (45)
Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells: down‐regulation upon myeloid differentiation (2004) (45)
Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation (2000) (45)
Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation (2001) (45)
Induction of Cellular Immune Responses in Patients With Stage-I Multiple Myeloma After Vaccination With Autologous Idiotype-pulsed Dendritic Cells (2011) (45)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. (2019) (44)
Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2013) (43)
A paternal methyl donor-rich diet altered cognitive and neural functions in offspring mice (2017) (43)
Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis (1997) (43)
Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis (2008) (43)
Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. (2007) (43)
Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. (1989) (43)
Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia (2017) (43)
Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. (2010) (43)
Comparative analysis of proliferative potential and clonogenicity of MACS‐immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor (2006) (43)
Absence of significant interaction of fluconazole with cyclosporin. (1989) (42)
A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells (2014) (42)
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years (2015) (42)
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia (2020) (42)
miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. (2011) (42)
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. (2010) (42)
Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. (2018) (42)
Influence of HLA on human partnership and sexual satisfaction (2016) (42)
No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. (2011) (42)
Population pharmacokinetics of oral busulfan in children (2002) (41)
Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. (1993) (41)
Shift of aberrant antigen expression at relapse or at treatment failure in acute leukemia. (2000) (41)
The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. (2001) (41)
Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. (2011) (41)
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma (2002) (41)
Phase IB Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Simultaneous Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine Consolidation in Newly Diagnosed Adult Patients (pts) with Acute Myeloid Leukemia (AML) under Age 61. (2006) (41)
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation (2003) (41)
Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells. (2020) (41)
8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. (1990) (41)
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT (2018) (41)
Mesenchymal stem cells efficiently inhibit the proinflammatory properties of 6-sulfo LacNAc dendritic cells (2009) (40)
Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells (2005) (40)
Electronic real-time assessment of patient-reported outcomes in routine care—first findings and experiences from the implementation in a comprehensive cancer center (2016) (39)
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. (2012) (39)
Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells (2017) (39)
Regional differences in HLA antigen and haplotype frequency distributions in Germany and their relevance to the optimization of hematopoietic stem cell donor recruitment. (2010) (39)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial (2019) (38)
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. (2018) (38)
Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients. (1987) (38)
Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells (2017) (38)
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells (2011) (38)
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. (2008) (38)
Cup-like acute myeloid leukemia: new disease or artificial phenomenon? (2008) (38)
Encouraging results in the treatment of haemorrhagic cystitis with estrogen – report of 10 cases and review of the literature (2000) (37)
8-METHOXYPSORALEN AND ULTRAVIOLET A THERAPY FOR CUTANEOUS MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE (1988) (37)
Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study (2005) (37)
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. (2002) (37)
Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. (2019) (37)
Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. (1995) (36)
Physical and functional characterization of the human LGI1 gene and its possible role in glioma development (2002) (36)
German consensus on immunogenetic donor search for transplantation of allogeneic bone marrow and peripheral blood stem cells (1997) (36)
T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation (2005) (36)
Breast carcinoma cells modulate the chemoattractive activity of human bone marrow‐derived mesenchymal stromal cells by interfering with CXCL12 (2015) (36)
CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. (2021) (36)
The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index. (2011) (36)
Flexible Antigen-Specific Redirection of Human Regulatory T Cells Via a Novel Universal Chimeric Antigen Receptor System (2014) (36)
A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. (2001) (35)
Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients (2012) (35)
Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis (2014) (35)
Thawing of cryopreserved mobilized peripheral blood--comparison between waterbath and dry warming device. (2002) (35)
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT (2017) (35)
Identification of 2127 new HLA class I alleles in potential stem cell donors from Germany, the United States and Poland (2014) (35)
Determination of mycophenolic acid and mycophenolate mofetil by high-performance liquid chromatography using postcolumn derivatization. (2001) (35)
Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss‐of‐function mutations (2005) (35)
Toward an Optimal Global Stem Cell Donor Recruitment Strategy (2014) (35)
Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation (2008) (35)
HLA-DP matching and graft-versus-host disease in allogeneic bone marrow transplantation. (1986) (35)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG (2012) (34)
Onkologie. 3-Stufen-Modell optimiert Behandlung unter Kostendeckung. Wie die künftigen Strukturen der onkologischen Versorgung in Deutschland aussehen sollten (2008) (33)
Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia (2009) (33)
Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting system (2014) (33)
Impact of ABO incompatibility on patients’ outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT (2017) (33)
Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. (2012) (33)
GFI1 as a novel prognostic and therapeutic factor for AML/MDS (2016) (33)
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study (2016) (33)
Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. (1991) (33)
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide (2017) (32)
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT (2016) (32)
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial (2011) (32)
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial (2014) (32)
High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. (2007) (32)
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV. (2009) (32)
Myasthenia gravis after BMT: identification of patients at risk? (1992) (32)
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer (2014) (31)
HLA‐DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia (2009) (31)
Efficacy of single‐dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma (2006) (31)
Criteria for initiation and evaluation of minority donor programs and application to the example of donors of Turkish descent in Germany (2009) (31)
FLT3 kinase inhibitors in the management of acute myeloid leukemia. (2007) (31)
Allogeneic Transplantation of CD34+ Selected Hematopoietic Cells—Clinical Problems and Current Challenges (2004) (31)
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. (2012) (31)
Supplementation with antioxidants prior to bone marrow transplantation. (1997) (31)
Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells (2001) (30)
Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. (1999) (30)
Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients. (2002) (30)
Safety and Efficacy of Itraconazole Compared to Amphotericin B as Empirical Antifungal Therapy for Neutropenic Fever in Patients with Haematological Malignancy* (2007) (30)
Successful eradication of acquired factor-VIII-inhibitor using single low-dose rituximab (2010) (30)
An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants (2018) (30)
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. (2018) (30)
CD34+‐enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add‐back (2002) (30)
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. (2002) (30)
Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites (2004) (30)
Simultaneous occurrence of Hodgkin's lymphoma and eosinophilic granuloma: a potential pitfall in positron emission tomography imaging. (2002) (30)
Clinical pharmacology of mitoxantrone. (1986) (30)
Second donation of granulocyte–colony‐stimulating factor–mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells (2005) (30)
MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells (2014) (29)
Lipidomic approach for stratification of acute myeloid leukemia patients (2016) (29)
Dynamics of epigenetic age following hematopoietic stem cell transplantation (2017) (28)
Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis (2018) (28)
The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial (2019) (28)
Impact of Different Exercise Programs on Severe Fatigue in Patients Undergoing Anticancer Treatment-A Randomized Controlled Trial. (2017) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). (2011) (27)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
Leukemic red bone marrow changes assessed by magnetic resonance imaging and localized1H spectroscopy (2005) (27)
WHO classification of myeloid neoplasms and leukemia. (2010) (27)
Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation (2008) (27)
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia (2012) (27)
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics (2009) (27)
Imatinib mesylate for targeting the platelet‐derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose‐escalation Phase I trial (2007) (27)
Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study (2012) (27)
F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan (2007) (27)
Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34+ cord blood-derived dendritic cells (2002) (27)
Isolation and structure elucidation of urinary metabolites of mitoxantrone. (1991) (26)
Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma (2007) (26)
Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34+ cells: regulation of Fas ligand gene expression in megakaryocytes. (2007) (26)
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT (2019) (26)
Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8+ T cell receptor alpha repertoire following allogeneic transplantation (2016) (26)
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long term disease control. An analysis from the Lymphoma Working Party Of the EBMT. (2016) (26)
Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia (2008) (26)
Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. (2013) (26)
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. (2011) (26)
Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen (2004) (26)
The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia—a report from the German Registry covering the period from 1998 to 2004 (2009) (26)
Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography. (1985) (25)
Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient (2017) (25)
Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. (1990) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Severe pernicious anemia with distinct cytogenetic and flow cytometric aberrations mimicking myelodysplastic syndrome (2012) (25)
Prediction of hematopoietic stem cell yield after mobilization with granulocyte–colony‐stimulating factor in healthy unrelated donors (2015) (25)
Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation. (2010) (25)
CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML. (2011) (24)
Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients (1990) (24)
Be smart against cancer! A school-based program covering cancer-related risk behavior (2014) (24)
Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia (2001) (24)
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia (2016) (24)
EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in Cholangiocarcinoma (2013) (24)
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts (2015) (24)
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment (2013) (24)
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial (2021) (24)
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. (1988) (23)
Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. (1998) (23)
Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin (2001) (23)
Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias (1999) (23)
Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. (2002) (23)
IL2‐ and IL4‐dependent proliferation of T‐cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogenous leukaemia (1992) (23)
Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study (2018) (23)
Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil (2010) (23)
Trans‐complementing adenoviral vectors for oncolytic therapy of malignant melanoma (2004) (23)
Selective recruitment of stem cell donors with rare human leukocyte antigen phenotypes (2007) (23)
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial (2016) (23)
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin’s disease (2004) (23)
The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial (2017) (23)
Identification of Uncommon Chromosomal Aberrations in the Neuroglioma Cell Line H4 by Spectral Karyotyping (2001) (23)
A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis (2004) (22)
Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC). (2012) (22)
Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor. (2018) (22)
Imatinib in breast milk (2009) (22)
Regional HLA Differences in Poland and Their Effect on Stem Cell Donor Registry Planning (2013) (22)
Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. (1997) (22)
Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody‐based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells (2014) (22)
The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians (2006) (22)
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity (2008) (22)
The role of pegfilgrastim in mobilization of hematopoietic stem cells. (2008) (22)
Efficacy and Side Effects of Granulocyte Collection in Healthy Donors (2013) (22)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) (2008) (22)
Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia (2010) (22)
Chlorpromazine Combined with Cidofovir for Treatment of a Patient Suffering from Progressive Multifocal Leukoencephalopathy (2008) (22)
Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model. (1995) (22)
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells (2019) (22)
Self-induction of Cyclophosphamide and Ifosfamide Metabolism by Repeated High-Dose Treatment (1986) (21)
Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. (2001) (21)
Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT (2019) (21)
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia (2013) (21)
Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model. (1999) (21)
Ghrelin/Leptin-imbalance in patients with primary biliary cirrhosis. (2004) (21)
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party (2016) (21)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT (2018) (21)
Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2 (2011) (21)
Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model (2017) (21)
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. (2006) (21)
Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association (2018) (21)
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation (2012) (20)
Helicobacter pylori vacA, iceA, and cagA status and pattern of gastritis in patients with malignant and benign gastroduodenal disease. (2001) (20)
Transplant results in adults with Fanconi anaemia (2018) (20)
Pretransplant Metabolic Distress Predicts Relapse of Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation (2015) (20)
Peripheral blood stem cell collection in allogeneic donors: impact of venous access (2012) (20)
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases (2003) (20)
Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population (2013) (20)
(18)F-FDG PET/MRI for therapy response assessment in sarcoma: comparison of PET and MR imaging results. (2015) (20)
Detection and separation of intracellular 1-beta-D-arabinofuranosylcytosine-5-triphosphate by ion-pair high-performance liquid chromatography. (1989) (20)
Pregnancy after bone marrow transplantation for severe aplastic anemia. (1987) (20)
Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. (2003) (20)
A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR (2019) (20)
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis (2004) (19)
INTERACTION OF FLUCONAZOLE WITH CYCLOSPORIN (1989) (19)
A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia (2016) (19)
Arsenic-induced APL differentiation in cerebrospinal fluid. (2007) (19)
Cancer patients’ control preferences in decision making and associations with patient-reported outcomes: a prospective study in an outpatient cancer center (2017) (19)
HPC enumeration with the Sysmex XE-2100 can guide further flow cytometric CD34(+) measurements and timing of leukaphereses. (2003) (19)
Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. (2008) (19)
Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma. (2005) (19)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) (19)
Haploidentical transplant in patients with myelodysplastic syndrome. (2017) (19)
Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia (2013) (19)
Retrospective Analysis of 37,287 Observation Years after Peripheral Blood Stem Cell Donation. (2017) (18)
MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML. (2015) (18)
Secretion of IL‐2, IL‐3, IL‐4, IL‐6 and GM‐CSF by CD4+ and CD8+ TCRαβ+ T‐Cell Clones derived early after Allogeneic Bone Marrow Transplantation (1993) (18)
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. (2005) (18)
PET/MRI Imaging in High-Risk Sarcoma: First Findings and Solving Clinical Problems (2013) (18)
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation (2019) (18)
Detection of herpesvirus and adenovirus co-infections with diagnostic DNA-microarrays. (2009) (18)
Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy (2011) (18)
FLUCONAZOLE VERSUS KETOCONAZOLE IN OROPHARYNGEAL CANDIDIASIS IN AIDS (1989) (18)
Bevacizumab for recurrent hemangioendothelioma (2011) (18)
Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine (2010) (18)
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients (2014) (18)
Expression profiling of gastric cancer samples by oligonucleotide microarray analysis reveals low degree of intra-tumor variability. (2005) (18)
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF. (2001) (17)
Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus (2007) (17)
Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis. (2007) (17)
Rapid and sustained influence of intravenous zoledronic Acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. (2007) (17)
After major ABO‐mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B (2005) (17)
188Re anti‐CD66 radioimmunotherapy combined with reduced‐intensity conditioning and in‐vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation (2010) (17)
Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia (2001) (17)
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia. (2019) (17)
Drug monitoring of quinine by HPLC in cerebral malaria with acute renal failure treated by haemofiltration (2004) (16)
Isolated pericardial relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia. (1989) (16)
Alemtuzumab Depletes Dendritic Cells More Effectively in Blood Than in Skin: A Pilot Study in Patients With Chronic Lymphocytic Leukemia (2007) (16)
Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway (2017) (16)
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations (2017) (16)
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. (1999) (16)
Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. (2019) (16)
Mitoxantrone metabolism in the isolated perfused rat liver (2004) (16)
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. (2011) (16)
Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV (2008) (16)
Expression of G1 Phase Cyclins in Human Gastric Cancer and Gastric Mucosa of First-Degree Relatives (2002) (16)
Skin involvement as the first manifestation of systemic aspergillosis in patients after allogeneic hematopoietic cell transplantation (2001) (16)
Putting insulin glargine and malignancies into perspective. (2009) (16)
Diabetes insipidus in a patient with a highly malignant B-cell lymphoma and stomatitis. (2012) (16)
Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study (2013) (15)
Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study. (2016) (15)
Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT. (2020) (15)
Expression of cyclin genes in human gastric cancer and in first degree relatives. (2002) (15)
MiR-134-mediated β1 integrin expression and function in mesenchymal stem cells. (2013) (15)
CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation (2004) (15)
Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial (2012) (15)
EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia (2020) (15)
Sex and body mass index but not CXCL12 801 G/A polymorphism determine the efficacy of hematopoietic cell mobilization: a study in healthy volunteer donors. (2013) (15)
Genomic aberrations in myeloid sarcoma without blood or bone marrow involvement: characterization of formalin-fixed paraffin-embedded samples by chromosomal microarrays. (2014) (15)
Experience with a Therapeutic Platelet Transfusion Strategy in Acute Myeloid Leukemia: Preliminary Results of a Randomized Multicenter Study After Enrolment of 175 Patients. (2009) (15)
Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia (2015) (15)
A Therapeutic Platelet Transfusion Strategy without Routine Prophylactic Transfusion Is Feasible and Safe and Reduces Platelet Transfusion Numbers Significantly: Preliminary Analysis of a Randomized Study in Patients after High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantat (2008) (15)
Unicar: A Novel Modular Retargeting Platform Technology for CAR T Cells (2015) (15)
Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over (2019) (15)
Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. (2009) (14)
Cunninghamella bertholletiae infection mimicking myocardial infarction. (1999) (14)
Improved assay for determination of busulfan by liquid chromatography using postcolumn photolysis. (2004) (14)
Dasatinib 140 Mg Once Daily (QD) Has Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Imatinib-Resistant or -Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 2-Year Data from CA180- 035 (2008) (14)
[Neurologic complications after bone marrow transplantation]. (1991) (14)
Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. (2004) (14)
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. (2017) (14)
Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV, (2011) (14)
Mitoxantrone in the treatment of relapsed and refractory acute leukemia. (1985) (14)
The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia (2019) (13)
Regulation of Down Syndrome Critical Region 1 expression by Nuclear Factor of Activated T cells in megakaryocytes (2009) (13)
In Vivo Chemical Screen in Zebrafish Embryos Identifies Regulators of Hematopoiesis Using a Semiautomated Imaging Assay (2016) (13)
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study (2019) (13)
Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome (2003) (13)
Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. (2002) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
Abdominal lymphomas, convulsive seizure and coma: a case of successfully treated, advanced Whipple's disease with cerebral involvement. (1998) (13)
Relations between IL-3-induced proliferation and in vitro cytokine secretion of bone marrow cells from AML patients. (1999) (13)
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML (2017) (13)
Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8 (2014) (13)
The anti-fungal agent itraconazole exerts immunosuppressive effects on alloreactivity but not on natural immunity in vitro. (1991) (13)
Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2009) (13)
Drug-induced changes in the expression of MDR-associated genes: Investigations on cultured cell lines and chemotherapeutically treated leukemias (2005) (13)
Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation. (1989) (12)
Severe Pulmonary Hypertension in Chronic Idiopathic Myelofibrosis (2004) (12)
5-Lipoxygenase inhibition by antifungal azole derivatives: new tools for immunosuppression? (1989) (12)
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients (2016) (12)
Die Pharmakokinetik von Adriamycin und Adriamycin-Metaboliten (1980) (12)
Foscarnet – an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? (2000) (12)
Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series (2014) (12)
Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir. (1988) (12)
The T_T genotype within the NME1 promoter single nucleotide polymorphism −835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia (2012) (12)
Allogeneic hematopoietic stem cell transplantation in ovarian cancer—the EBMT experience (2010) (12)
Follow-up of 12,559 Unrelated Donors of Peripheral Blood Stem Cells or Bone Marrow (2010) (12)
Accidental busulfan overdose during conditioning for stem cell transplantation (2005) (12)
[131I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma (1989) (12)
Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation (2002) (12)
Regulation of fas/fas ligand‐mediated apoptosis by nuclear factor of activated T cells in megakaryocytes (2012) (12)
Immunohistology of the human spleen after bone marrow transplantation for leukemia with special reference to the early post-transplantation period. (1990) (11)
Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV (2010) (11)
What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease? (2018) (11)
The isolation and identification of indigo and indirubin from urine of a patient with leukemia. (1989) (11)
Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. (2000) (11)
Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas (2008) (11)
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring (2015) (11)
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q (2016) (11)
Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. (1990) (11)
Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia (2012) (11)
Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy (1999) (11)
Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia (2018) (11)
Correlation between low CSA plasma concentration and severity of acute GvHD in bone marrow transplantation (1988) (11)
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. (2021) (11)
Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. (1986) (11)
Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia? (2014) (11)
Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing (2016) (11)
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma (2002) (10)
CHRONIC GRAFT‐VERSUS‐HOST DISEASE AND HLA‐DR4 IN THE SOUTHERN GERMAN POPULATION (1990) (10)
Thalidomide--the need for a new clinical evaluation of an old drug. (1993) (10)
Drug resistance testing of acute myeloid leukemia in adults using the MTT assay. (1999) (10)
Successful transplantation of CD34+ selected peripheral blood stem cells from an unrelated donor in an adult patient with Diamond–Blackfan anemia and secondary hemochromatosis (2005) (10)
Cytotoxic response of human regulatory T cells upon T-cell receptor-mediated activation: a matter of purity (2014) (10)
A novel method for direct and fluorescence independent determination of drug efflux out of leukemic blast cells. (1997) (10)
Secretion of IL-2, IL-3, IL-4, IL-6 and GM-CSF by CD4+ and CD8+ TCR alpha beta+ T-cell clones derived early after allogeneic bone marrow transplantation. (1993) (10)
Appearance of an inherited porphyria cutanea tarda in a child after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. (1986) (10)
Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia (2011) (10)
Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation (2005) (10)
The pathogenesis of myelodysplastic syndromes (MDS) (2007) (10)
Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT (2018) (10)
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide. (1992) (10)
MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells (2015) (10)
Mitoxantrone and cyclophosphamide in patients with advanced breast cancer. (1984) (10)
Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation. (2013) (10)
Sun Protection Training Based on a Theater Play for Preschoolers: an Effective Method for Imparting Knowledge on Sun Protection? (2013) (10)
Bone marrow transplantation in comparison with conventional therapy in children with adult type chronic myelogenous leukemia. (1990) (10)
Resolution of Gastrointestinal Protein Loss after Helicobacter pylori Eradication in a Patient with Hypertrophic Lymphocytic Gastritis (2004) (9)
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. (2002) (9)
A case of accidental cyclosporin overdose with pharmacokinetic analysis. (1988) (9)
GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome (2016) (9)
TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity (2013) (9)
Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study. (2016) (9)
Comparison of flow cytometry and laser scanning cytometry for the analysis of CD34+ hematopoietic stem cells (2004) (9)
Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry (2019) (9)
Mitoxantrone in the treatment of relapsed and refractory acute leukemia (2004) (9)
Validation of the ELN 2017 Classification for AML with Intermediate Risk Cytogenetics with or without NPM1 -Mutations and High or Low Ratio FLT3-ITD s (2017) (9)
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2021) (9)
Evidence for a graft-versus-tumor effect in refractory ovarian cancer (2003) (9)
Flow cytometric DNA-quantification of three-color immunophenotyped cells for subpopulation specific determination of aneuploidy and proliferation. (2001) (9)
Detection and identification of human urinary metabolites of biantrazole (CI-941). (1993) (9)
The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease. (1998) (9)
[Bone marrow transplantation in severe aplastic anemia]. (2008) (9)
Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. (2019) (9)
Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells (2019) (9)
Lymph node morphology after allogeneic bone marrow transplantation for chronic myeloid leukemia: a histological and immunohistological study focusing on the phenotype of the recovering lymphoid cells (1988) (9)
Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML (2021) (9)
Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors (2020) (8)
Allogeneic Stem Cell Transplantation Confers a Favorable Outcome in Patients with NPM1 Positive Acute Myeloid Leukemia: Results From a Donor Vs. No-Donor Analysis of 309 Patients Treated in the SAL AML-2003 Trial (2011) (8)
A Questionnaire Study to Assess the Value of the Vulnerable Elders Survey, G8, and Predictors of Toxicity as Screening Tools for Frailty and Toxicity in Geriatric Cancer Patients (2016) (8)
The Prevalence of Extramedullary AML Detected By 18-FDG/PET-CT: Results from the Prospective PET-AML Trial (2014) (8)
Intimal Pulmonary Artery Sarcoma Presenting as Severe Dyspnea and Right Heart Insufficiency (2010) (8)
Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial (2020) (8)
The High Prevalence of FLT3-ITD Mutations Is Associated with the Poor Outcome in Adult Patients with t(6;9)(p23;q34) Positive AML - Results of an International Metaanalysis. (2007) (8)
Minimal-Residual Disease Guided Treatment with Azacitidine in MDS/AML Patients at Imminent Risk of Relapse: Results of the Prospective RELAZA2 Trial (2017) (8)
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study * (2021) (8)
Allogeneic Bone Marrow Transplantation for Childhood Acute Lymphoblastic Leukemia in Second Remission After Intensive Primary and Relapse Therapy (2003) (8)
Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation (1996) (8)
Forum: Letters to the Editor (2000) (8)
Regulation of interferon- g gene expression by nuclear factor of activated T cells (2001) (8)
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). (2015) (8)
Cytotoxic and proliferative functions of T lymphocyte clones derived very shortly after allogeneic bone marrow transplantation. (1991) (8)
IFN-gamma and TNF-alpha secretion by CD4+ and CD8+ TCR alpha beta + T-cell clones derived early after allogeneic bone marrow transplantation. (1993) (8)
Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden (2015) (8)
Support of Unrelated Stem Cell Donor Searches by Donor Center-Initiated HLA Typing of Potentially Matching Donors (2011) (8)
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion. (2015) (8)
Double lumen port access in patients receiving allogeneic blood stem cell transplantation (2001) (8)
The German competence network ‘Acute and chronic leukemias’ (2004) (8)
Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-α (wellferon) (2004) (8)
Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia (2002) (8)
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone? (2011) (8)
Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML. (2004) (8)
Redirection of Immune Effector Cells by Bispecific Antibody Systems for the Treatment of Acute Myeloid Leukemia (2011) (8)
Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone. (1994) (8)
A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia (1988) (7)
Fluorescence in situ hybridization for the BCR/ABL rearrangement is dependent on the percentage of nonlymphocytic cells in peripheral blood stem cell harvests. (1998) (7)
Biotransformation of CI-937 in primary cultures of rat hepatocytes. Formation of glutathione conjugates. (1995) (7)
Single-Dose Pegfilgrastim after Chemotherapy Is Highly Effective in Enhancing the Mobilization of Autologous CD34+ Peripheral Blood Stem Cells in Patients with Lymphoid Malignancies and Solid Tumors. (2004) (7)
Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2. (1990) (7)
Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV (2010) (7)
Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells (2017) (7)
Remission of a lymphoproliferative disorder occurring after second BMT from an unrelated donor in a 5-year-old boy with severe aplastic anemia. (1995) (7)
[Bone marrow transplantation in chronic myeloid leukemia. Influence of gnotobiotic measures, especially antiviral prophylaxis]. (2008) (7)
Differences Between CEBPA bZIP and TAD Mutations and Their Effect on Outcome-an Analysis in 4578 Patients with Acute Myeloid Leukemia (2016) (7)
Complex cytogenetic and immunophenotypic aberrations in a patient with Sezary syndrome. (1996) (7)
Predictive strength of mixed lymphocyte cultures for acute graft-versus-host disease in patients transplanted with HLA-identical sibling bone marrow. (1989) (7)
Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia (2014) (7)
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. (1987) (7)
Pelvic magnetic resonance imaging after bone marrow harvest – a retrospective study in 50 unrelated marrow donors (2005) (7)
Secondary Malignancies in CML Patients – Data From the German CML Study IV (2012) (7)
High density FTA plates serve as efficient long-term sample storage for HLA genotyping. (2014) (7)
A Strong Immune Effect by Allogeneic Stem Cell Transplantation May Improve Survival in AML Patients with a High Ratio of the FLT3-ITD Mutation to the Wt-FLT3 Allele: Results from an Analysis of 257 Patients Treated in the SAL AML-2003 Trial (2011) (7)
Feasibility of Imatinib Combination Therapies in a Randomized Trial for Chronic Myeloid Leukemia: The German CML-Study IV - Pilot Phase. (2004) (7)
Plasma levels of granulocyte colony-stimulating factor in patients after allogeneic bone marrow transplantation for chronic myeloid leukemia correlate with engraftment of transplanted marrow (1997) (7)
Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS) (2016) (7)
Improved Killing of AML Blasts By Dual-Targeting of CD123 and CD33 Via Unitarg a Novel Antibody-Based Modular T Cell Retargeting System (2015) (7)
Complete remission of gastric high-grade B-cell malt lymphoma after cure of helicobacter pylori infection (2000) (6)
Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia (2017) (6)
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis (2021) (6)
A highly sensitive method for the detection of PKC412 (CGP41251) and its metabolites by high-performance liquid chromatography. (2007) (6)
Pulmonary adverse events in unrelated donors of peripheral blood stem cells (2013) (6)
Etablierung eines interdisziplinären Krebszentrums im Spannungsfeld interner und externer Interessen (2007) (6)
Tregs activated by bispecific antibodies (2015) (6)
Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All‐trans Retinoic Acid and Chemotherapy‐containing Regimens (2017) (6)
Splenectomy for chronic thrombotic thrombocytopenic purpura (1990) (6)
A Rapid Flow Cytometric Method for the Detection of NPM1 Mutated Patients with Acute Myeloid Leukemia (AML). (2008) (6)
Enhancing The Efficacy and Specificity Of Antibody-Based T Cell Retargeting Strategies Against Hematological Malignancies (2013) (6)
Rapid infusion of amphotericin B: is it safe, effective, and wise? (1995) (6)
Prophylaxe und Therapie von Pilzinfektionen in der Onkologie (1995) (6)
Allogeneic bone marrow transplantation in childhood leukemia: results and strategies in the Federal Republic of Germany. (1990) (6)
Juvenile chronische Leukämie und chronische myelomonozytäre Leukämie : Erfahrungen mit der Knochenmarktransplantation im Kindesalter anhand von 5 Fällen (1992) (6)
New approaches to the prophylaxis and treatment of bacterial and fungal infections in allogeneic marrow transplant recipients. (1994) (6)
[Bone marrow transplantation in acute leukemia, chronic myeloid leukemia, severe aplastic anemia and stage IV neuroblastoma. Effect of antiviral prevention with anti-CMV-hyperimmunoglobulin and acyclovir]. (1986) (6)
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial (2015) (6)
The oxidative biotransformation of losoxantrone (CI-941). (2002) (6)
Psychoonkologische Aspekte in der Versorgung von Prostatakarzinompatienten (2015) (6)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation (2006) (6)
Consolidation Therapy Is Associated with Significantly Lower Bleeding Risk Compared to Induction Therapy in Patients with Acute Myeloid Leukemia (2014) (6)
Genome-wide analysis of histone H 3 acetylation patterns in AML identifies PRDX 2 as an epigenetically silenced tumor suppressor gene (2012) (6)
Yersinia pseudotuberculosis causing abscesses in a 31-year-old patient in the post-immunosuppression period after allogeneic HSCT (2009) (5)
Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. (2007) (5)
Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. (1990) (5)
Class I HDAC SNP analysis in healthy donors compared to AML patients (2007) (5)
Pain Perception in Patients Undergoing Bone Marrow Puncture—A Pilot Study (2004) (5)
Efficiency of HLA-A, -B, -C, -DRB1 High-Resolution Typings of Newly Recruited Potential Stem Cell Donors. (2006) (5)
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians (2016) (5)
Prevention of CMV infection after BMT in high-risk patients using CMV hyperimmune globulin. (1988) (5)
Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML (2022) (5)
Brain tissue concentration of mitoxantrone in the rat in relation to in vitro chemosensitivity of malignant human intracranial tumors--preliminary results. (1989) (5)
Comparative in vitro toxicity of mitoxanatrone and adriamycin in human granulocyte-macrophage progenitor cells (2004) (5)
Candida‐Mykosen in der Hämatologie/Onkologie. Aspekte zu Epidemiologie, Diagnostik, Prophylaxe und Therapie: Candida mycoses in hematology/oncology. Aspects of epidemiology, diagnosis, prophylaxis and treatment (1999) (5)
Decrease of Alpha‐Tocopherol and Beta‐Carotene by High‐Dose Radiochemotherapy Preceding Bone Marrow Transplantation (1989) (5)
An Intergroup Randomised Trial of Standard Intensity Versus Reduced Intensity TBI-Based Conditioning In Patients with Acute Myeloid Leukemia in First Complete Remission (2011) (5)
Successful combination of anti‐cd33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia (2003) (5)
Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer. (2009) (5)
Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV. (2009) (5)
Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission (2005) (5)
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia. (1986) (5)
Trabectedin in the Neoadjuvant Treatment of High-Grade Pleomorphic Sarcoma: Report of a Rare Case and Literature Review (2013) (5)
Marriage does not relate to major histocompatibility complex: a genetic analysis based on 3691 couples (2020) (5)
Induction Treatment In Elderly Patients with Acute Myeloid Leukemia (AML): Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) In 492 AML Patients >60 Years – Results From the SAL 60plus Trial (2010) (5)
Bone marrow transplantation in children with neuroblastoma. (1989) (5)
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV (2012) (5)
Implementation and first results of a tablet-based assessment referring to patient-reported outcomes in an inpatient cancer care unit. (2017) (5)
Acute Myeloid Leukemia in the Elderly Is Characterized By a Distinct Genetic Landscape (2015) (5)
The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells (2009) (5)
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia (2021) (5)
Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Acute Myeloid Leukemia (2011) (5)
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD,NPM1- or biallelicCEBPA mutations. (2017) (5)
Hematopoietic cell graft safety (2009) (5)
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma (2001) (5)
Experiences of the Dresdner Cord Blood Bank, supported by the Deutsche Knochenmarkspenderdatei. (1999) (5)
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells. (2004) (5)
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) (5)
Computer-based quality control in high-dose chemotherapy and bone marrow transplantation (1998) (5)
Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia (2006) (5)
Reconstitution of 6-Sulfo LacNAc Dendritic Cells After Allogeneic Stem-Cell Transplantation (2012) (5)
patients with acute myeloid leukemia ( AML ) mutations in 1485 adult NPM 1 Prevalence and prognostic impact (2006) (5)
Steady State Mobilization of Autologous Blood Stem Cells Using G-CSF and AMD3100 in Patients with Multiple Myeloma (MM). (2006) (4)
Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression. (2017) (4)
Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“ (2004) (4)
Akute myeloische Leukämie (AML) (2006) (4)
The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial (2015) (4)
Risk Stratification and Prognostic Factors in Elderly AML Patients – Updated Results of 909 Patients Entered Into the Prospective AML96 Trial. (2009) (4)
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning (4)
Is There a Risk in Allogeneic PBPC Donation for Autoimmune Diseases Due to Short-Term Treatment with rhG-CSF? Preliminary Results of a Prospective Study in 100 Unrelated Stem Cell Donors. (2004) (4)
Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia (2018) (4)
Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation (2008) (4)
Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy (2004) (4)
[Lung changes caused by Mycobacterium xenopi infection in a patient with bone marrow transplantation: problems in differential diagnosis]. (1991) (4)
Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial (2015) (4)
Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. (2018) (4)
Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil (1990) (4)
Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis (2013) (4)
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia. (1986) (4)
Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer. (2016) (4)
[Immune thrombocytopenia, anemia and leukopenia during pregnancy. Successful therapy with extracorporeal immunoadsorption]. (1997) (4)
CXCR4 blockade and Sphingosine‐1‐phosphate activation facilitate engraftment of haematopoietic stem and progenitor cells in a non‐myeloablative transplant model (2014) (4)
[Disseminated aspergillosis and mucormycosis. A case report]. (1996) (4)
A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma (2017) (4)
[Therapy of peritoneal carcinosis with intraperitoneal administration of cis-diamminedichloroplatinum and systemic sodium thiosulfate protection. Clinical results of a pilot study and pharmacokinetics]. (1985) (4)
[The value of bone marrow transplantation in the treatment of leukemia]. (1993) (4)
Siltuximab for Multicentric Castleman Disease—Letter (2015) (4)
Evaluation of procollagen-III peptide as a marker for veno-occlusive disease after bone marrow transplantation (1996) (4)
Graft Versus Host Disease Prophylaxis with Everolimus and Tacrolimus in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukaemia (AML) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). (2006) (4)
Mutations of the Nucleophosmin (NPM1) Gene Are Common in Adult Acute Myeloid Leukemia and Associated with Favorable Prognosis If Present without FLT3-ITD Mutation. (2005) (4)
Therapy of acute graft-versus-host disease (2010) (4)
Allogeneic Stem-Cell Transplantation for Patients with De Novo Acute Myeloid Leukemia Not in Complete Response: Results of a Survey from the European Group for Blood and Bone Marrow Transplantation (EBMT). (2004) (4)
Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression (2017) (4)
Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography. (1994) (4)
A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial (2010) (4)
Net reclassification improvement with serial biomarkers and bed-sided spirometry to early predict the need of organ support during the early post-transplantation in-hospital stay in allogeneic HCT recipients (2018) (4)
Chimeric antigen receptor T-cell therapy in acute myeloid leukemia (2022) (4)
FLT3mutation Assay Laboratory Cross Validation: Results from the CALGB 10603/Ratify Trial in Patients with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) (2018) (4)
Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial, (2011) (4)
Prophylaxe und Therapie von Cytomegalie-Infektionen nach Knochenmarktransplantation (1984) (4)
Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study (2013) (4)
5–azacitidine Treatment of Imminent Relapse Defined by Decreasing Donor CD34+ Progenitor Subset Chimerism in Patients with CD34+ High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) after Allogeneic Stem Cell Transplantation. (2008) (4)
Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients (2016) (4)
Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation (2013) (4)
Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML (2022) (3)
[Leucocytosis: etiology and diagnostic approach]. (2007) (3)
Flow Cytometric Detection of Minimal Residual Disease One Year Post Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with B-CLL. (2009) (3)
Metabolisierung und Ausscheidung von Adriamycin (1981) (3)
The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes (2015) (3)
Specificity of immunophenotyping in acute promyelocytic leukemia. (2000) (3)
Diagnostik und Therapie der akuten myeloischen Leukämie des Erwachsenen (2006) (3)
Transplant activities in Germany in 1998 – a survey facilitated by the National Registry for Hemopoietic Stem Cell Transplantation (2000) (3)
Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial (2020) (3)
IN-SITU HYBRIDISATION FOR DETECTION OF CYTOMEGALOVIRUS IN LIVER FROM PATIENTS AFTER MARROW GRAFTING (1988) (3)
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2 (2017) (3)
[Pharmacokinetics of cisplatin in long-term hemodialysis treatment]. (1989) (3)
Immunogene Thrombozytopenie, Anämie und Leukopenie während Schwangerschaft: Erfolgreiche Extrakorporaltherapie mit Immunadsorption (2008) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
[Anterior wall infarct in an 18-year-old patient with Hodgkin's disease. Possible relation between mediastinal irradiation, accelerated arteriosclerosis and vincristine chemotherapy]. (2008) (3)
Formation of reactive intermediates by cytochrome P-450 mediated oxidation of the anticancer drug mitoxantrone (1994) (3)
Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients (2003) (3)
Individualisierte Therapie der akuten myeloischen Leukämie (2012) (3)
Reply to: ‘Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity’ by Kern et al. (2011) (3)
Increased myelotoxicity of idarubicin: is there a pharmacological basis? (2003) (3)
Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation (2018) (3)
Antiviral treatment of Influenza A (H1N1-09) guided by molecular resistance testing in aplasia after allo-SCT (2011) (3)
[Determinants of serum pentamidine concentration in the human]. (1992) (3)
Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome (2014) (3)
[Oral prophylaxis of herpes infections using acyclovir following bone marrow transplantation: a clinical and clinico-pharmacological study]. (1986) (3)
Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: Interim results of a prospective, open-label trial. (2004) (3)
Bone marrow transplantation from unrelated donors in chronic myelogenous leukemia. (1993) (3)
Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD. (2004) (3)
Approaches to managing volunteer marrow donor registry HLA data. Algorithms for directing donor center-initiated HLA-DR typing of selected donors. (2000) (3)
Induction of Toll-like receptor 2 and 4 expression on CD4+ and CD8+ T cells in G-CSF-mobilized unrelated peripheral blood stem cell grafts during leukapheresis: impact on patient outcome (2008) (3)
Klinische Studien in der Onkologie - 2013 und zukünftig (2013) (3)
Matched Unrelated Donor Stem Cell Transplantation for Patients with Diffuse Large Cell B Cell Lymphoma: A Retrospective Analysis of 118 Patients Registered through the European Group for Blood and Marrow Transplantation (EBMT). (2006) (3)
Phase I-trial of clebopride, a new antiemetic, in chemotherapy — induced nausea and vomiting (2006) (3)
PET-CT Scan for Detection of Extramedullary Acute Myeloid Leukemia (2010) (3)
Petreatment with Rituximab Reduces the Incidence of Chronic Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation in Patients with B Cell Lymphoma. (2004) (3)
Minimal Residual Disease (MRD) Based Preemptive 5–Azacytidine Treatment Can Prevent or Delay Imminent Relapse In Patients with High-Risk MDS or AML After Allogenic HSCT – Results of the “RELAZA” Trial (2010) (3)
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia (1995) (3)
CT und HR-CT in der Diagnostik pulmonaler Komplikationen bei Knochenmarktransplantation (1994) (3)
AF1q Is a Novel Poor Prognostic Marker for Adult Acute Myelogenous Leukemia (AML) Patients with Normal Cytogenetics. (2005) (3)
Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine (2010) (3)
Mixed response after allogeneic haemopoietic-cell transplantation for metastatic renal-cell carcinoma. (2004) (3)
Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide. (2007) (3)
JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia-Letter. (2018) (3)
sensitive detection of imminent relapse after allogeneic stem cell transplantation (2009) (2)
Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the “LENAMAINT” Trial (2011) (2)
Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin (2017) (2)
Midazolam: Significant Pain Reduction in Patients Undergoing Bone Marrow Puncture - a Clinical Trial. (2004) (2)
Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: Effects on cytokine production and suppressor cell status (1991) (2)
Allogeneic hematopoietic SCT for patients with autoimmune diseases (2009) (2)
Interaction of Cytosine Arabinoside Accumulation and Cytosine Arabinoside Triphosphate Formation with Various Cytotoxic Drugs (1992) (2)
HLA-DP matching in allogeneic bone marrow transplantation. (1987) (2)
Disposition of Clebopride after Intravenous Administration (1992) (2)
Some limitations in the detection of residual aneuploid cells with dna quantification on immunophenotyped cells by flow cytometry (2000) (2)
Molecular Long-Term Surveillance of CML Patients on Imatinib Therapy. Follow-Up of German Patients Treated within the IRIS Trial. (2004) (2)
[Status of clinical trials in oncology--2013 and onwards]. (2013) (2)
Gene Expression Profiling in AML with Normal Karyotype: A Multicenter Study Investigating Molecular Markers in 252 Cases (2008) (2)
Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial (2011) (2)
No Benefit of Combining Additional Compounds with Standard High Dose Cytarabine Consolidation: Results of the Prospective Randomized AML2003 Study (2011) (2)
Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT (2022) (2)
[Precancerous risk markers in Helicobacter pylori gastritis]. (2001) (2)
Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV (2011) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Acute myeloid leukemia cells fail to activate native human dendritic cells: a potential mechanism of immune evasion (2010) (2)
Making the Case for Private Cord Blood Banking: Mission Failed! (2010) (2)
Antigen-Specific Redirection of Human Regulatory T Cells by Bispecific Antibodies, (2011) (2)
Magenlymphome und Gastrointestinale Stromatumoren (GIST) (2004) (2)
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. (2023) (2)
[The pharmacokinetics of adriamycin and adriamycin-metabolites (author's transl)]. (1980) (2)
Mutations of the SHP-2 Proteine Tyrosine Phosphatase in Adult Patients with Acute Myeloid Leukemia. (2004) (2)
Bildung und Steuerung des Universitäts KrebsCentrum Dresden (2017) (2)
Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis (2013) (2)
Comparable Outcome after Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated and Sibling Donors in Elderly Patients with Acute Myeloid Leukemia - Results of a Retrospective Analysis in 368 Patients. (2007) (2)
Development of a Bispecific Antibody-Releasing Stem Cell System for the Eradication of Acute Myeloid Leukemia Blasts Via Redirected Immune Effector Cells (2014) (2)
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration. (1987) (2)
Dendritic Cells Generated outof Blasts from Patients with Acute Leukemia (2001) (2)
High BAALC Expression as an Independent Adverse Risk Factor in 309 Patients with Acute Myeloid Leukemia (AML) and Normal Cytogenetics: Results of the SHG’96 Study. (2004) (2)
Cross-trial networking in AML: a step forward rather than corner cutting. (2004) (2)
Pharmacokinetics of Imatinib and its Main Metabolite N-desmethyl-imatinib (2004) (2)
Indikationen zur Chemotherapie bei Tumoren von Ösophagus, Magen und Pankreas (2002) (2)
Oral Prophylaxis of Herpes Infections with Acyclovir (ACV) After BMT (1985) (2)
Optimizing management of myelodysplastic syndromes post-allogeneic transplantation (2011) (2)
Oral Etoposide Is Equivalent to Intravenous Administration within the CHOEP-Regimen - Results of a Comparative Pharmacokinetic Study. (2006) (2)
Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis (2010) (2)
Increased expression of cyclooxygenase-2 (COX-2) in gastric carcinoma and in the gastric mucosa of healthy first-degree relatives (2000) (2)
[Diagnostics and therapy of acute myeloid leukemia]. (2009) (2)
Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group (2010) (2)
The Calcineurin/NFAT Signaling Pathway Is a Target for the Collagen Type I-Induced Calcium Response in Megakaryocytes and Mediates Expression of Megakaryocytic Genes. (2007) (2)
Ileal perforation in a patient with Crohn’s disease while receiving recombinant human growth hormone therapy (2007) (2)
A Genome Wide shRNA Screen In Primary Human AML Cells Identifies ROCK1 As a Novel Therapeutic Target (2013) (2)
CMV prophylaxis in hematopoietic-cell transplantation. (2014) (2)
Prophylactic platelet transfusion. (2013) (2)
Rapid Risk-Profiling Including Fast Donor Search within a Multi-Center Trial Allows for Early Allogeneic Stem Cell Transplantation during Aplasia in Patients with High-Risk Acute Myeloid Leukemia. (2004) (2)
Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX (2004) (2)
Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) (2)
Zur behandlung konnataler Varizellen mit Aciclovir (1987) (2)
Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia. (2009) (2)
Supportive Care Only Versus Allogeneic Hematopoietic Cell Transplantation in Patients ≥ 60 Years with De Novo High-Risk MDS. (2009) (2)
Epigenetic Biomarkers Are Applicable for Risk Stratification in Myelodysplastic Syndromes (2016) (2)
Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing (2014) (2)
Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia. (2004) (2)
EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) (2)
The Impact of Transfusion-Dependency on the Outcome of Patients with Myelodysplastic Syndromes (MDS) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation after Myeloablative Conditioning. (2007) (2)
Evaluation of Various Strategies to Generate NPM1mut-Specific T Cell Clones (2016) (2)
Early Allogeneic Hematopoietic Cell Transplantation during Induction Chemotherapy in High-Risk Acute Myeloid Leukemia. (2004) (2)
Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV. (2010) (2)
management and outcome of Cml-blast crisis: Results from the randomized Cml study Iv : V907 (2014) (2)
Knochenmarktransplantation bei akuter Leukämie, chronisch myeloischer Leukämie, schwerer aplastischer Anämie und Neuroblastom Stadium IV. Einfluß antiviraler Prophylaxe mit Anti-CMV-Hyperimmunglobulin und Azyklovir (1986) (2)
The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia – results of two cohort studies involving 215 patients and 3759 controls (2018) (2)
Clonal Hematopoiesis in AML Patients in Hematological CR Is Present in Many Patients with Intermediate Risk AML and Is Associated with a High Prevalence of DNMT3A gene Mutations (2014) (2)
[The Dresden Cord Blood Bank. Experiences of the Cord Blood Bank in Dresden, promoted by the German bone Marrow Donor Registry]. (2000) (2)
Expression of cyclins in gastric carcinoma and in the gastric mucosa of first-degree relatives (2000) (2)
Long-term follow-up of patients with relapsed or refractory non-Hodgkin’s lymphoma receiving allogeneic stem cell transplantation (2016) (2)
Oxygen Tension Regulates Hematopoietic Stem Cell Migration Into An in-Vitro Niche Beneath Mesenchymal Stromal Cells. (2009) (2)
Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas (2019) (2)
SAT0549 Autologous hematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) – a ebmt retrospective survey (2018) (1)
Induktions- und intensivierte Konsolidationstherapie der akuten myeloischen Leukämie des Erwachsenen (1988) (1)
Akute myeloische Leukämie (2017) (1)
Pharmakokinetik von Cisplatin bei chronischer Hämodialyse-Behandlung (2008) (1)
Aufbau der Deutschen Knochenmarkspenderdatei (2008) (1)
Das Kompetenznetzwerk „Akute und chronische Leukämien” (2004) (1)
Intrakavitäre Therapie mit Mitoxantron: eine pharmakokinetische Auswertung (1987) (1)
Pharmakokinetische Aspekte bei der Therapie maligner Ergüsse (1988) (1)
Multimodale Therapiekonzepte bei gastrointestinalen Stromatumoren (GIST) (2007) (1)
TNM-Klassifikation maligner Tumoren: Neue Auflage 1987 (1987) (1)
Präkanzeröse Risikomarker der Helicobacter-pylori-Gastritis (2001) (1)
Zur Situation klinischer Studien in Deutschland (2013) (1)
Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL) (2016) (1)
Zwischenergebnisse der Deutschen Morbus Hodgkin-Therapiestudie (1986) (1)
Orale Prophylaxe von Herpes-Infektionen mit Acyclovir nach Knochenmarktransplantation: Eine klinische und klinisch-pharmakologische Untersuchung (1986) (1)
Vorwort (2013) (1)
An approach to ex vivo expansion of stem cells (1999) (1)
Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies 1 (2000) (1)
Abstract 2209: Rapidly switchable universal CAR-T cells with improved safety profile allow for active targeting of PD-L1 expressing solid tumors (2020) (1)
[Juvenile chronic leukemia and chronic myelomonocytic leukemia. Experiences with bone marrow transplantation in childhood in 5 cases]. (1992) (1)
Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD (2022) (1)
Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation – a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients (2011) (1)
Successful bone marrow transplantation from an unrelated donor in a child with AML in second remission (1987) (1)
Targeting leukemia using an inducible universal chimeric antigen receptor (UniCAR) T cell technology (2017) (1)
SDF-1/CXCR4 blockade to mobilize hematopoietic progenitor cells from the placenta (2010) (1)
Surveillance cultures and benefit of laminar airflow units in patients undergoing bone marrow transplantation (2005) (1)
[A rare coagulation disorder. Diagnostics and management in cases of hereditary dysfibrinogenemia]. (2009) (1)
[Gastric MALT lymphoma and gastrointestinal stromal tumors (GIST)]. (2004) (1)
[Transplantation of bone marrow from unrelated donors in chronic myeloid leukemia]. (2008) (1)
Allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome (MDS) (2007) (1)
Loss of Heterozygosity in Acute Myeloid Leukemia with Normal Karyotype. (2006) (1)
Sézary syndrome: infiltration of the gastric wall—does it matter? (2012) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure. (2009) (1)
Factors Determining Survival after Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia (2008) (1)
TBI technique and clinical results of leukemia patients at the University of Tübingen. (1990) (1)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with FLT3-ITD-Negative and NPM1-Wild Type Intermediate Risk (ELN) Acute Myeloid Leukemia (2016) (1)
Risk Stratification Using a New Prognostic Model for Patients with Secondary Acute Myeloid Leukemia - Results of the DSIL-AML96 Trial. (2009) (1)
Constitutional SAMD9L Mutations Cause Familial Myelodisplastic Syndrome with Monosomy 7 and Stable Revertant Mosaicism (2017) (1)
BPI A645G SNP but Not NOD2 Genotype Predicts for Acute Lung Injury After Allogeneic Stem Cell Transplantation (2010) (1)
MiRNA Expression Signatures in Acute Myeloid Leukemia Are Predictors for Patient Outcome. (2006) (1)
Randomized comparison of 90 mg versus 60 mg daunorubicin in 7+3 standard induction for newly diagnosed acute myeloid leukemia : Results from the SAL-DaunoDouble trial (2018) (1)
Hypoxia Increases IL-8 Secretion of Mesenchymal Stroma Cells Affecting Migratory Capacity in An Autocrine Manner (2008) (1)
An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML). (2007) (1)
Detection of HBV DNA in the blood of a stem cell donor after G-CSF treatment. (2016) (1)
and no independent prognostic relevance as analysed in 1766 patients classification in acute myeloid leukemia (AML) has no correlation with age Multilineage dysplasia according to the World Health Organisation (WHO) (2013) (1)
Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST) (2014) (1)
Randomized, Double-Blind, Placebo-Controlled Trial of Oral Budesonide for Prophylaxis of Acute Intestinal Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (PROGAST) (2011) (1)
Reply to Inokuchi et al (2006) (1)
Molecular Detection of Minimal Residual Disease Based on NPM1-Real-Time PCR At the Time of Complete Remission Is a Strong Predictor of Disease Free and Overall Survival in AML (2011) (1)
Azacytidine Compromises NK-Cell Activity in AML and MDS Patients Undergoing MRD-Based Pre-Emptive Treatment After Allogeneic Stem Cell Transplantation (2012) (1)
HELYX study I & II: treatment of low-grade gastric lymphoma of mucosa-associated lymphoid tissue (MALT) type stages I & III. first analysis of 26 patients (2003) (1)
HLA Class I-Specific Effects in AML with Mutated Nucleophosmin (2016) (1)
8-OR: PRIMER DESIGN FOR SHORT AMPLICON-BASED NGS (2013) (1)
A NME1 promoter SNP predicts Ara-C associated neurotoxicity in AML patients. (2011) (1)
MicroRNA Mir-23a Regulates SDF-1alpha Expression in Human Bone Marrow-Derived Mesenchymal Stem Cells (2008) (1)
[Clinical research within the German competence net "acute and chronic leukemias"]. (2006) (1)
Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL) (2014) (1)
Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT (2022) (1)
[Candidiasis in cancer patients: Epidemiology, diagnosis, prophylaxis and therapy]. (1999) (1)
Time Dependent Decrease in Efficacy of Second G-CSF Mobilization in Healthy Unrelated Donors (2015) (1)
Prevalence and Prognostic Impact of RUNX1 Mutations In Patients with Acute Myeloid Leukemia (AML): A Study In 1649 Patients Registered In the AML96 Protocol of the DSIL/SAL (2010) (1)
Allogeneic stem cell transplantation improves survival inpatients with AML characterized by a high allelic ratio ofmutant FLT3-ITD (2016) (1)
[Initial experiences with pentamidine aerosol in prevention of Pneumocystis carinii pneumonia following bone marrow transplantation]. (1990) (1)
Reduced-Intensity Conditioning (RIC) with Busulfan, Fludarabine and Campath-1H Is Complicated by a High Rate of Graft Failure and Severe Viral Complications in Patients with CLL. (2004) (1)
Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer. (2016) (1)
Bone marrow transplantation for acute leukemia in second or subsequent remission (1984) (1)
Predictors for the Efficacy of Peripheral Blood Progenitor Cell (PBPC) Collection–Results from 4050 Harvests Performed in a Single Centre (2008) (1)
Dysmyelopoiesis In Healthy Bone Marrow Donors (2010) (1)
Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
Multidrug-Related Protein 1 (MRP1) Polymorphisms rs129081, rs212090, and rs212091 Predict Survival In Acute Myeloid Leukemia (2013) (1)
Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia (2010) (1)
[Setting up an interdisciplinary cancer center between the poles of internal and external interests]. (2007) (1)
Monitoring of Donor Chimerism in CD34+ Peripheral Blood Progenitors Allows to Detect Minimal Residual Disease after Allogeneic Stem Cell Transplantation -Results of a Randomized Trial (2008) (1)
Evaluation of Clinical Judgement at Initiation of AML-Therapy in Elderly Patients - A Prospective Randomized Trial. (2007) (1)
[Risk factors and prevention of pneumocystis carinii pneumonia after bone marrow transplantation]. (1992) (1)
Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT) (2001) (1)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Related Donor in Chronic Myeloid Leukemia (CML): An Explanation for Fast Improvement of Survival in Two Consecutive German CML Studies. (2009) (1)
Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes (2015) (1)
Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial (2019) (1)
Differences in Reconstitution of NK-Cell Subsets and Expression of Effector Molecules after HLA-Identical and Haploidentical Allogeneic Stem Cell Transplantation in Patients with AML. (2005) (1)
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial- (2021) (1)
Feasibility and Efficacy of Peripheral Blood Progenitor Cell Mobilisation with Pegfilgrastim for Allogeneic Stem Cell Transplantation. (2004) (1)
Hip Pain in Medulloblastoma as First Symptom of Extraneural Relapse (2011) (1)
Abstract 2176: Using a PSMA-specific low-molecular-weight compound for prostate cancer treatment with rapidly switchable universal CAR-T cells: Overcoming the challenges of cellular immunotherapies in solid tumors (2020) (1)
[Clinical research in the "acute and chronic leukemias"competence network ]. (2004) (1)
Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS) (2009) (1)
Preliminary results of a multicenter phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer. (2009) (1)
Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution (2004) (1)
- Updated Results from the Bridge Trial: Long-Term Survival and Impact of Donor Availability - Clofarabine Salvage Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML (2014) (1)
Differences in the Expression of Adhesion Molecules and Mobilization Efficacy in Healthy Stem Cell Donors and Patients with Hematologic Malignancies. (2004) (1)
Immunological Monitoring of Cancer Patients During a Phase I/II Clinical Trial of Natural Interleukin-2 (1990) (1)
Mismatched Unrelated Donor Allo-SCT for AML after Reduced Intensity or Ablative Conditioning Regimen—A Report from the Acute Leukemia Working Party of the EBMT (2015) (1)
[Accumulation of German bone marrow donor data]. (1994) (1)
Erratum to: "Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of in Vivo T Cell Depletion" [Biol Blood Marrow Transplant 2015;21:1754-1760]. (2017) (1)
Comparison of CXCR-4 and Adhesion Molecule Expression in Healthy Bone Marrow with Expression in Bone Marrow and Peripheral Blood of Patients Receiving G-CSF Plus AMD3100. (2005) (1)
Abstract B099: The UniCAR system: Inducible CAR T cells for precise reactivity and high efficacy against hematopoietic malignancies (2016) (1)
External Validation of the Revised PAM Score for Patients with AML Scheduled for Allogeneic Hematopoietic Stem Cell Transplantation (2016) (1)
PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia (2018) (1)
CD133+ Purified Hematopoietic Stem Cells in Co-Culture with Mesenchymal Stromal Cells - The Cell to Cell Contact Matters. (2007) (1)
Bone marrow transplantation in childhood leukemia in West Germany. (1987) (1)
Abstract 1506: Expansion kinetics and cytokine profiles of UniCAR-T-CD123, a rapidly switchable two-component CAR-T therapy, in patients with relapsed/refractory AML (2021) (1)
Rhinocerebral zygomycosis and subsequent treatment decisions in a young patient with AML. (2009) (1)
Sequential Combination of Azacitidine and Lenalidomide Can Target the TP53 -Mutated Clone in Del(5q) Higher-Risk Myelodysplastic Syndromes (2012) (1)
[Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group]. (1996) (1)
Real life experience with ATRA-arsenic trioxide based regimen in acute promyelocytic leukemia - results of the prospective German intergroup Napoleon registry (2016) (1)
Identification of a novel HLA-Cw*07 variant (Cw*0714) in a German Caucasian family. (2000) (1)
Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT (2015) (1)
Quality of life in patients with soft tissue sarcoma undergoing palliative treatment: A multicenter, cluster-randomized trial within the Germany Interdisciplinary Sarcoma Group (GISG-12). (2018) (1)
Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup. (2006) (1)
BACOPP-D - An Etoposide-Free Dose-Escalated Polychemotherapy Regimen in Advanced Hodgkin Lymphoma. (2007) (1)
Abstract 2313: Improved killing of tumor cells by a novel flexible antibody-based modular T cell retargeting system (2016) (1)
The Prognostic Impact of the Revised IPSS Cytogenetic Scoring System for Patients with MDS Allows a Risk-Stratification for Patients with MDS-Derived Acute Myeloid Leukemia (2012) (1)
High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia (2011) (1)
Erratum: Allogeneic hematopoietic SCT for patients with autoimmune diseases (Bone Marrow Transplantation (2009) vol. 44 (27-33) 10.1038/bmt.2008.424) (2009) (1)
Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer (2022) (1)
miRNA-23 a mediates post-transcriptional regulation of CXCL 12 in bone marrow stromal cells by (2014) (1)
Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF (2001) (1)
[The competence network "acute and chronic leukemias"]. (2004) (1)
Human Leukocyte Antigen Distribution in German Caucasians with Advanced Ewing’s Sarcoma (2012) (1)
Association of Skin and Blood Dendritic Cells with Acute Graft Versus Host Disease after Human Haematopoetic Cell Transplantation. (2004) (1)
Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup. (2007) (1)
Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C Plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia (2010) (1)
Prognosis of Adult Patients ≤60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups. (2005) (1)
Loss Of H3K27 Trimethylation (H3K27me3) Associates With a Multi Drug Resistance Phenotype In Acute Myeloid Leukemia (AML) (2013) (1)
[Treatment of congenital varicella with acyclovir]. (1987) (1)
[Pharmacokinetic aspects in the use of new cytostatic drugs]. (1987) (1)
Pharmacokinetics of High-Dose Etoposide Given in Diluted or Undiluted Form (1992) (1)
[Incidence, therapy and prevention of cytomegalovirus disease after bone marrow transplantation]. (1992) (1)
IL-2 Treatment in a Patient with Stage IV Neuroblastoma After Allogeneic Bone Marrow Transplantation (1990) (1)
[Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics]. (1986) (1)
Questions about the role of granulocyte-macrophage colony-stimulating factor as adjunct to non-Hodgkin's lymphoma chemotherapy. (1994) (1)
Kontinuierliche Infusion von natürlichem Interleukin 2 (n IL-2) zur Behandlung maligner Erkrankungen: Phase-I-Studie (1990) (1)
Bone Marrow or Peripheral Blood Stem Cell Transplantation From Unrelated Donors in Adult Patients With Acute Myeloid Leukemia (2011) (0)
Coexistence of a Heterozygous JAK2(V617F) Mutation and a Secondary BCR-ABL Translocation within the Compartment of Committed Myeloid Progenitors in Chronic Idiopathic Myelofibrosis. (2006) (0)
ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT (2017) (0)
Im Fokus - der ältere Patient (2/04) (2005) (0)
Pernicious Anemia Mimicking MDS by Del(3p) in Cytogenetics and Monocytic Leukemia in Trephine Biopsy by Highly Expression of CD163 Positive Cells (2011) (0)
Long-Term Follow-Up of 5,930 Unrelated Volunteers Donating Bone Marrow or Peripheral Blood Stem Cells. (2004) (0)
9431 POSTER Whole-body-PET/MRI a New Way of Imaging in Soft Tissue Sarcomas (2011) (0)
P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS (2022) (0)
Development of early gastric cancer 4 years after complete remission of Helicobacter pylori-associated gastric low-grade B-cell malt lymphoma (2000) (0)
Osteomyelosclerosis, Anemia and Extramedullary Hematopoiesis in Mice Deficient for the Transcription Factor NFAT (Nuclear Factor of Activated T Cells) c2 (2008) (0)
Allogeneic Transplantation of Purified Peripheral Blood Stem Cells from Unrelated Donors (1998) (0)
Ongoing Clinical Trials (2016) (0)
Plerixafor As a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers (NCT01954914) (2016) (0)
Influence of allogeneic bone marrow transplantation on the endocrine system in children. (1989) (0)
[Results and current status of bone marrow transplantation with unrelated donors]. (1987) (0)
Mitoxantrone and etoposide in refractory acute myelogenous leukemia (1986) (0)
Successful Adoptive Immunotransfers in a Boy with Relapse of T-ALL After Bone Marrow Transplantation from an Unrelated Donor (1994) (0)
Retrospective Analysis of Minimal Residual Disease-Guided Preemptive Treatment in Patients with AML and MDS - the SAL Study Group Experience (2015) (0)
Antiinflammatory and antiangiogenetic effect of ramiprilat: Angiotensin converting enzyme inhibition in monocytes prevents their angiotensin II- and hypoxia-induced cytokine expression by downregulation of AT-1 receptor expression and NF-kappaB activation (2003) (0)
Abstract 4430: Loss of the histone methyltransferase EZH2 induces chemoresistance in acute myeloid leukemia (AML) (2015) (0)
Early Versus Late Allogeneic Hematopoietic Cell Transplantation in Patients with AML - Results From the Randomized AML 2003 Trial (2013) (0)
ORIGINAL ARTICLE The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia (2009) (0)
[Symptomatic cyst of the pancreas and asymptomatic bilateral phaeochromocytoma] (2001) (0)
Hypoxia Alters the Main Characteristics of the Hematopoietic Stem and Progenitor Cell Microenvironment in Vitro (2011) (0)
patients age and no independent prognostic relevance as analyzed in 1766 MLD according to the WHO classification in AML has no correlation with (2013) (0)
Flowcytometric Detection of Aneuploidies in Acute Lymphoblastic Leukemia (ALL) Before and After Chemotherapy (1997) (0)
Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation. (2010) (0)
Pretransplant NPM1 -MRD Levels Predict Outcome after Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia (2015) (0)
MYELOID NEOPLASIA RNAi pro ﬁ ling of primary human AML cells identi ﬁ es ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug (2015) (0)
prognostic factor for relapse and survival in AML The level of residual disease based on mutant NPM1 is an independent (2013) (0)
A novel epigenetic resistance mechanism to the FLT3 inhibitor PK412 induces cross-resistance to standard chemotherapy in acute myeloid leukemia (AML). (2016) (0)
Bone marrow transplantation in leukemia in the absence of an HLA-identical sibling donor. (1987) (0)
cytomegalovirus infection after bone marrow transplantation Lymphocytopenia as an unfavorable prognostic factor in patients with (2011) (0)
Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation (2012) (0)
Acute Erythroleukemia Morphology Does Not Confer an Unfavourable Prognosis in Itself. Results of a Subgroup Analysis of the Prospective Randomized AML96-, AML2003 and AML60+ Studies of the Study Alliance Leukemia (SAL) (2012) (0)
Evaluation of Vulnerable Elders Survey, G8 questionnaire and Predictors of Toxicity as screening tools for frailty and toxicities in geriatric patients with cancer. (2015) (0)
Differences in the Localization of Receptor Tyrosine Kinase FLT3 in Human Hematopoietic Stem and Progenitor Cells and Leukemic Blasts. (2006) (0)
Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia (2013) (0)
Clinical research in the competence network "acute and chronic leukemias" (2004) (0)
Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Myelodysplastic Syndromes 50 Years or Older. A Retrospective Survey from the EBMT. (2006) (0)
Allogeneic hematopoietic cell transplantation in patients 60 to 70 years of age with de novo high-risk MDS or secondary AML – a comparison with patients lacking donors who received azacitidine Biol Blood Marrow Transplant (2015) (0)
Repression of retinoic acid receptor signaling by Ski in prognostically unfavorable forms of acute myeloid leukemia (2004) (0)
Distinct types of donor and recipient T cell clones functionally related to host-v-graft reactivity and autologous remission after bone marrow transplantation for severe aplastic anemia. (1987) (0)
Main Session I (2002) (0)
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years (2021) (0)
Cellular and Molecular Events Underlying the Interaction of Hematopoietic Stem and Progenitor Cells with Mesenchymal Stem Cells. (2005) (0)
A Single Nucleotide Polymorphism Of Growth Factor Independence 1 (GFI136N) is a Novel Prognostic Marker For The Progression Of Myelodysplastic Syndrome To Acute Myeloid Leukemia (2013) (0)
Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome (2022) (0)
The 10.000/μl Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients (2001) (0)
Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy. (2004) (0)
Flow Cytometric Response Monitoring in MDS with Del(5q) Using a Simple 5-Parameter-Score - an Elnet Imds-Flow Experience (2016) (0)
Prediction of Response to Treatment with Lenalidomide in Patients with Non-Del 5q Myelodysplastic Syndrome by Gene Expression Profiling Remains Difficult. (2009) (0)
GemtuzumabOzogamicin as Part of Reduced-Intensity Conditioning forAllogeneic Hematopoietic CellTransplantation in Patients with Relapsed AcuteMyeloid Leukemia (2008) (0)
Title Pages / DGHO-Symposium. Zertifizierung in der Medizin / Table of Contents (2012) (0)
26 Collection of peripheral blood stem cells in allogeneic donors via femoral venous lines - safe, successful and well-tolerated (2010) (0)
Comparison of Growth Patterns of Acute Myeloid Leukemia Cells In Vitro and In Vivo by Flow Cytometry (1997) (0)
Gene-Chip Analysis of Cord Blood Derived CD34+ Cells Expanded on Bioartificial Materials. (2004) (0)
Allogeneic blood stem cell transplantation. (2009) (0)
Gfi1 as a new target and predictive marker in AML (2014) (0)
The distinct genetic and epigenetic landscape of elderly AML: Data of the SAL registry (2016) (0)
Im Fokus: Gastrointestinale Tumoren (2008) (0)
Bone marrow transplantation in childhood leukaemia--experience and strategies in the Federal Republic of Germany. (1989) (0)
Im Fokus - Bronchialkarzinom (2005) (0)
Mir-10a Regulates Autophagy and Cell Cycle in Normal Karyotype Acute Myeloid Leukaemia (2016) (0)
Impact of Conditioning Regimen on Outcomes of T-Replete Haplo-Identical Transplantation for Patients Over 45 Years-Old with AML: A Study On Behalf Of the Acute Leukemia Working Party of the EBMT (2017) (0)
Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease (2014) (0)
Haploidentical Transplantation Outcomes for Secondary Acute Myeloid Leukemia—on Behalf of the ALWP of the EBMT (2018) (0)
Allogeneic stem cell transplantation in patients with Ph-negative Bcr/Abl-negative Chronic Myelogenous Leukemia : a retrospective study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation (2016) (0)
Prognostic role of microRNA polymorphisms in advanced gastric cancer patients. (2017) (0)
Comparing the Value of Serum Ferritin, Transfusion History and Magnetic Resonance Imaging for the Prediction of Iron Overload In MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation. (2010) (0)
1111 Pharmacogenetics of peripheral neuropathy in elderly patients (> 65years) with advanced gastric cancer receiving oxaliplatin based chemotherapy within a randomized phase II study (2009) (0)
Adverse Prognosis in Acute Myeloid Leukemia with Abnormality Abn(3q): Does EVI1 Matter? (2015) (0)
hematopoietic stem cell transplantation in acute myeloid leukemia Conditioning with 8 Gy total body irradiation and fludarabine for allogeneic (2013) (0)
The HCT-Specific Comorbidity Index Fails to Predict Survival After Allogeneic HCT In High Risk AML Patients - A Single Center Experience (2010) (0)
Bone Marrow Transplantation from an Unrelated Donor: Experiences in Children (1994) (0)
[Prophylaxis and therapy of fungal infections in oncology]. (1995) (0)
The Campath-Level at the Day of Transplant Predicts T-Cell Engraftment after Allogeneic Stem Cell Transplantation. (2006) (0)
Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis. (2010) (0)
A Distinct Immunophenotypic Profile Of Del(5q) MDS Allows For Fast Monitoring Of Response To Treatment With Lenalidomide Or Azacitidine (2013) (0)
[International bone marrow donor exchange]. (1989) (0)
Every-other-day feeding extends lifespan but fails to delay many symptoms of aging in mice (2017) (0)
TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation (2013) (0)
Treat How I treat hyperleukocytosis in acute myeloid leukemia (2015) (0)
Comparison of Different Techniques for the Detection of FLT3-Mutations in Exons 14/15 and 20 in Patients with Acute Myeloid Leukemia. (2006) (0)
Localization of Hematopoietic Stem Cells in Coculture with Mesenchymal Stromal Cells Impacts on Phenotype and Cell Cycle Status (2008) (0)
Cytotoxic Activity Of Bispecific Antibody-Redirected Human Regulatory T Cells: Fact Or Artifact (2013) (0)
Severe Pulmonary Adverse Events in Healthy Unrelated Donors of Peripheral Blood Stem Cells Following G-CSF Administration, (2011) (0)
Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial (2020) (0)
Toxicogenomic profiling of fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) in advanced gastric cancer: A translational study of the German Arbeitsgemeinschaft Internistische Onkologie (AIO). (2010) (0)
ROR1 Specific T Cell Clones from Healthy Individuals Show Common T Cell Receptor Motifs (2016) (0)
Discontinued at Least 90 Days Before the Procedure Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Interferon-? Before Allogeneic Bone Marrow Transplantation in Chronic (2013) (0)
Whole-body PET/MR in soft tissue sarcoma (STS) patients. (2012) (0)
Title Pages / Disclosure Statement / AYA-Workshop der DGHO – Besondere Behandlungs- und Betreuungsnotwendigkeiten bei jungen Krebspatienten / Table of Contents (2011) (0)
Association of the 1580 (C/T) Polymorphism in the Surfactant Protein B Gene with the Severity of Respiratory Failure after Allogeneic Transplantation. (2004) (0)
allogeneic hematopoietic stem cells Conditioning with fludarabine and targeted busulfan for transplantation of (2013) (0)
Busulphan conditioning Accidental busulfan overdose during conditioning for stem cell transplantation (2005) (0)
Multilineage dysplasia according to the World Health Organisation (WHO) classification in acute myeloid leukemia (AML) has no correlation with age and no independent prognostic relevance as analysed in 1766 patients Short title: Multilineage dysplasia in AML (2007) (0)
Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations (2017) (0)
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation (2022) (0)
Knochenmarktransplantationen durch Neubau Hämatologie/Onkologie in Dresden möglich : Kreibsleiden : Aktuelle Diagnostik und Therapie (1997) (0)
Why Work-Up Requests for HSCT Donors Fail – Reasons and Ways to Improve From a Donor Center Perspective (2011) (0)
Hematopoietic Progenitor Cells Harbouring BCR-ABL Exhibit Increased Adhesiveness but an Impaired Migration and Homing Potential. (2006) (0)
Treatment of High Risk AML and MDS with Ara-C-Containing Standard Chemotherapy Followed by Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC-SCT) during Aplasia: A Survey of the German Cooperative Transplant Study Group (GCTSG). (2006) (0)
Inhibition of PDGFRβ by Imatinib Mesylate Suppresses Proliferation and Alters Differentiation of Human Mesenchymal Stem Cells In Vitro. (2006) (0)
Pre-Transplant Weight Loss and Total Serum Protein Predict Relapse Of Acute Myeloid Leukaemia After Allogeneic Stem Cell Transplantation (2013) (0)
Sun Protection Training Based on a Theater Play for Preschoolers: an Effective Method for Imparting Knowledge on Sun Protection? (2013) (0)
The Impact of Donor Type In Patients with AML and High Risk Cytogenetic Aberrations (2010) (0)
ASSOCIATION BETWEEN THE EGFR-R497K POLYMORPHISM AND OVERALL SURVIVAL IN PATIENTS WITH ADVANCED CANCER OF THE HEAD AND NECK RECEIVING CETUXIMAB BASED TREATMENT (2011) (0)
Plasma Concentrations and AUC of Pegfilgrastim Have No Impact on Its Efficacy in Peripheral Blood Progenitor Cell Mobilization. (2005) (0)
Cup-Like AML - New Disease or Morphological Phenomenon?. (2006) (0)
1013-lbp: identification of 2127 new HLA alleles in potential donors registered with DKMS donor centers in Germany, the United States and Poland (2014) (0)
Pharmacogenetic profiling of treatment related toxicity in patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction treated with modified FOLFOX in combination with docetaxel (FLOT) (2007) (0)
Regulation of β1-Integrin by Mir-134 in Mesenchymal Stromal Cells – Implications for Mesenchymal Stromal Cell Adherence and Hematopoietic Stem Cell Interaction (2012) (0)
The coexpression of the migration inhibiting factor 1-alpha with CD401 in human atherosclerotic plaques is associated with advanced plaque stages and extent of intraplaque inflammation (2003) (0)
Long-term Follow Up of a Prospective Multicenter Trial with a High-Dose Cytosine Arabinoside and Daunorubicin Postremission Therapy in Adults with De Novo Acute Myeloid Leukemia (1997) (0)
EGFR polymorphisms in bile tract cancers. (2006) (0)
T Cells + and CD4 + Tumor Cells by CD8 Prostate Stem Cell Antigen-Expressing Bispecific Antibodies Mediate Killing of Novel Humanized and Highly Efficient (2012) (0)
P-059 Distribution of clonal cells in flow cytometry-defined subpopulations of patients with myelodysplastic syndromes (MDS) (2013) (0)
Role of hnRNP K and Interacting mRNAs in Pathogenesis of AML with 9q Deletion (2018) (0)
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial. (2023) (0)
Gewinn durch palliative Chemotherapie (CTx) solider Tumoren aus Sicht der Patienten (2010) (0)
Focal Positivity for Non-Specific Esterase in AML: A Surrogate Marker to Predict AML with t(8;21)/RUNX1-RUNX1T1 (2011) (0)
ORIGINAL ARTICLE Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia (2006) (0)
Donor Lymphocyte Infusion Vs. Second Allogeneic HCT In Relapsed AML After Allografting: A Landmark Analysis From The Acute Leukemia Working Party Of EBMT (2013) (0)
„Start Speaking Stop Smoking“ – ein Praxisbeispiel für Tabakprävention an Berufsbildenden Schulen (2014) (0)
Outcome of Patients with Primary Refractory Acute Myeloid Leukemia (AML) Undergoing Myeloablative Allogeneic Stem-Cell Transplantation (alloSCT) from HLA-Identical Sibling: Favorable Outcome in a Subset of Patients. (2006) (0)
Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG (2013) (0)
Prediction of Hematopoietic Stem Cell Yield after Mobilization with GCSF in Healthy Unrelated Donors (2014) (0)
VEGF receptor 1 and heparanase expression as prognostic factors in cholangiocellular carcinoma. (2011) (0)
1010-lbp: Simulation of potential stem cell donor searches: Available matching donor is not always identified (2014) (0)
German AML Intergroup (2004) (0)
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years (2022) (0)
Interaction Between Center Effect and Strategy for Graft Vs. Host Disease Prophylaxis on Outcome of T-Cell Depleted and T-Cell Replete Haploidentical Transplants, an Analysis on Behalf of ALWP-EBMT (2016) (0)
Isolation and Structure Elucidation of Urinary Metabolites of Mitoxantrone1 (2006) (0)
H1N1-09 Infections In Patients with Hematologic or Oncologic Malignancies: A Single-Centre Experience (2010) (0)
[Special treatment and management requirements in young cancer patients]. (2011) (0)
Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome - Results of a Phase I/II Trial. (2004) (0)
Single-Chain Bispecific Antibodies Retargeting of Human Regulatory T Cells by (2011) (0)
Yield Prediction of Nucleated Cells As Well As CD34+ Progenitors in Allogeneic Bone Marrow Harvests Depends on Differentially Important Biological Donor Variables. A Retrospective Single Center Analysis of 1275 Allogeneic Bone Marrow Collections (2015) (0)
Duration of Unrelated Donor Search for Hematopoietic Stem Cell Transplantation (2011) (0)
Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation (2010) (0)
[The status of intraperitoneal chemotherapy]. (1989) (0)
Vorwort (2011) (0)
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse (2022) (0)
Role of the ABC-transporters ABCC4, ABCC5 and ABCC11 in response to chemotherapy in adult patients with acute myeloid leukemia (2005) (0)
Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup (2010) (0)
Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations. (2004) (0)
Defining the Leukemia Epigenome: Distinct Genome Wide Histone H3 Modification Patterns Exist in AML, ALL and Healthy Hematopoietic Progenitor Cells. (2007) (0)
6618 Results of a multi-center phase II study of imatinib and fluorourcail/leucovorin (FU/LV) in patients with unresectable or metastatic gallbladder or biliary tract cancer (2009) (0)
Lack of association between the frequencies of HLA-DR or HLA-DP alleles and the occurrence of chronic graft-versus-host disease. (1991) (0)
Haemopoietic precursor cell toxicity of mitoxantrone (1986) (0)
[Induction and intensive combined therapy of acute myeloid leukemia in adults]. (1988) (0)
Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy. (2012) (0)
syndromes via the canonical Wnt pathway Erythropoietin inhibits osteoblast function in myelodysplastic Version 3 HAEMATOL / 2017 / 172726 (2017) (0)
Beneficial Effects of G-CSF Dosage Adaption in Allogeneic Stem Cell Donors That Are at Risk for Poor Mobilization. Retrospective Dual Center Analysis of 5691 Allogeneic Stem Cell Mobilizations (2015) (0)
Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid (2000) (0)
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer (2014) (0)
Factors Influencing Peripheral Blood Progenitor Cell Yield After 2nd Mobilization With G-CSF In Allogeneic Donors (2013) (0)
POTENTIAL ROLE of 8-COLOR FLOW CYTOMETRY for CHARACTERIZATION of MDS with Del(5q) ABNORMALITIES (2011) (0)
Screening for Hemoglobinopathies in Allogeneic Cord Blood Units Using Capillary Electrophoresis (2011) (0)
Allogeneic Hematopoietic Stem Cell Transplantation Provides Cure for Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) : A Retrospective Study of The Chronic Malignancies and Inborn ErrorsWorking Parties (CMWP and IEWP) of The EBMT (2017) (0)
Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS) (2014) (0)
Regulatory Potential of miRNAs on CXCL12 Expression in Human Mesenchymal Stem Cells (MSC) (2011) (0)
Pharmacokinetic Aspects of Etoposide Therapy — A Review (1994) (0)
“Human Development Index” Correlates with Rates and Influences Outcome of Hematopoietic Stem Cell Transplantation for Patients with Acute Leukemia. (2009) (0)
Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemias (SAL) (2008) (0)
Molecular Characterization Of The Anti-Leukemic Effects Of Single Agent Eltrombopag (2013) (0)
Acute Myeloid Leukemia: An Update of Treatment Results with High-Dose Ara-C Consolidation Therapy (1992) (0)
Elderly Patients with Acute Myeloid Leukemia Are Not All the Same: Results of the Prospective DSIL AML96 Trial. (2007) (0)
[Place of hematopoietic stem cell transplantation in the treatment of myelodysplastic syndromes]. (2001) (0)
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients (2016) (0)
Breast carcinoma cells modulate main characteristics and functional properties of human bone marrow-derived mesenchymal stromal cells in a non-contact dependent manner (2011) (0)
Long-term experience after cure of Helicobacter pylori infection in low grade gastric MALT lymphomas: A follow-up study on 50 patients. (1997) (0)
Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial (2021) (0)
Prognostic role of interleukin-1B and interleukin-1-receptor antagonist polymorphisms in localized gastric cancer. (2011) (0)
P-259 Therapy-related MDS after curative intensive therapy for de novo acute myeloid leukemia – An emerging clinical entity? (2013) (0)
Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge Trial – (2012) (0)
[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. (2016) (0)
Heilung eines enteralen Eiweißverlustes durch Helicobacter pylori-Eradikation bei lymphozytärer Riesenfaltengastritis (2004) (0)
Profiling of Aberrant DNA Methylation In AML Reveals Subclasses of CpG Islands with Epigenetic or Genetic Association (2010) (0)
HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age (2016) (0)
Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts <10G/L (2014) (0)
Clinical-grade manufacturing of switchable CAR-T cells in an automated closed system for phase I/II trials (2018) (0)
Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML (2003) (0)
Expression and Functional Analysis of Autotaxin, a Relevant Motility and Survival Factor, in FLT3-ITD Positive Acute Myeloid Leukemia and Primary Hematopoietic Stem Cells. (2008) (0)
Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target (2014) (0)
P020 Functional characterization of adult mesenchymal stromal cells from patients with myelodysplastic syndrome (2007) (0)
One-Mutation Model Can Explain Age Incidence in AML Carrying Nucleophosmin (NPM1) Mutations. (2007) (0)
com-Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study (2019) (0)
Long Term Follow up and Impact of Comorbidity Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML - Lessons Learned from the Prospective Bridge Trial - (2016) (0)
Association between DNA-repair gene and glutathione S-transferase gene polymorphisms and clinical outcome in patients (pt) with localized non-small cell lung cancer (NSCLC) treated with sequential radiochemotherapy. (2011) (0)
Long-Term HSC Donor Follow-up: Malignancy Incidences after Donation Are Identical Compared to a Matched Control Sample of Registered Donors, but Different to Expected General Population Rates (2015) (0)
199 LiverFailureontheBackgroundofPseudocirrhosis inPatientswithLiverMetastasisfromBreastCancer, WhoRespondedtoTreatment (2015) (0)
HLA-DP matching in bone marrow transplantation (1993) (0)
Detection of Herpesvirus and Adenovirus Infections in Patients Undergoing Stem Cell Transplantation: Looking Below the Tip of the Iceberg with the Microarray Technology. (2007) (0)
Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-α-treated chronic myelogenous leukaemia patients (2005) (0)
The 10/NL Trigger for Prophylactic Platelet Transfusion in Acute Myeloid Leukemia: A Prospective Comparative Multicenter Study (1997) (0)
Reciprocal Regulation of DSCR1 (Down Syndrome Critical Region 1) Expression and NFAT (Nuclear Factor of Activated T Cells) Activation in Megakaryocytes. (2007) (0)
72 PERSONALIZED TREATMENT APPROACH FOR GFI136N HETEROZYGOUS OR HOMOZYGOUS MDS PATIENTS (2015) (0)
Estimating the Chances of Older AML Patients to Achieve a Complete Remission Upon Intensive Induction Chemotherapy - An AMLCG and SAL Study (2010) (0)
New thalidomide derivatives, a process for their preparation and the use thereof in pharmaceuticals (1992) (0)
Im Fokus: Präventive Onkologie (2011) (0)
Gfi136N is a prognostic marker and possible target for the progression of MDS to AML (2014) (0)
C022 Lenalidomide treatment modulates proliferation and differentiation of human mesenchymal stromal cells from healthy donors and MDS patients (2009) (0)
Genetische Veränderungen bei malignen Tumorerkrankungen des Menschen : Kreibsleiden : Aktuelle Diagnostik und Therapie (1997) (0)
Late effects and quality of life (2nd Section) (2001) (0)
Regulation of Fas/Fas Ligand-Mediated Apoptosis in Megakaryocytes by Nuclear Factor of Activated T Cells. (2009) (0)
Similar outcome of different treatment strategies in patients 16 to 60 years of age with acute myeloid leukemia (AML) (2008) (0)
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide Running title : MSC in MDS subtypes and effect of lenalidomide (2013) (0)
Kurzmitteilungen/Short Communications. Eine neue Rubrik der Onkologie (1986) (0)
BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation (2017) (0)
Hämatopoetische Stammzelltransplantation und zelluläre Immuntherapie (2004) (0)
Labile Plasma Iron Predicts for Survival in Patients Undergoing Allogeneic Stemcell-Transplantation – Results from the Prospective Multicenter German-Austrian Allive Trial (2017) (0)
In memoriam Mildred Scheel (1985) (0)
[Secondary high-grade MALT lymphoma of the stomach in a 69-year-old patient with gastrocolic fistula]. (2001) (0)
Im Fokus: Supportivtherapie mit G-CSF (2007) (0)
FDG PET/MR for therapy response assessment in sarcoma. (2013) (0)
Targeting Mycophenolate Mofetil for Graft-Versus-Host Disease Prophylaxis after Allogeneic Blood Stem Cell Transplantation. (2006) (0)
Impact of gamma/delta TCR+, Foxp3+ and Toll-Like Receptor Expressing T-Cells on the Outcome of Patients Receiving Unrelated Peripheral Blood Stem Cell Transplantation. (2006) (0)
Molecular characteristics of FLT3 mut ETP-ALL versus FLT3 wt ETP-ALL patients. (2013) (0)
Integrated Analysis of Global DNA Methylation and Transcription Reveals a Leukemia Subtype with Extreme Hypermethylation Associated with Silencing of Regulators of Differentiation (2018) (0)
Unrelated Hematopoietic Blood Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML) in First Remission. (2006) (0)
Lack of the Transcription Factor NFAT (Nuclear Factor of Activated T cells) c2 in Hematopoietic Progenitor Cells Results in Profound Hematological Abnormalities in Mice (2011) (0)
[Continuous infusion of natural interleukin 2 (n IL-2) in treatment of malignant diseases: phase I study]. (1990) (0)
A Unique Case of a Donor Cell Acute Myeloid Leukemia Reveals Complex Kinetics of Mutations and Evolution of the Disease (2012) (0)
Functional Influence of CXCL12 Regulating miRNAs in Mesenchymal Stem Cells (MSCs). (2012) (0)
Toll-Like Receptor 2 and 4 Are Expressed on Transplanted T-Cell Subsets and Influence Outcome after Allogeneic Unrelated Peripheral Blood Stem Cell Transplantation. (2007) (0)
Effects of a Home-Based Exercise Intervention Program on Physical Capacity and Fatigue in Patients with Myelodysplastic Syndrome (MDS) - a Feasibility Study (2015) (0)
Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony‐stimulating factor treatment (2016) (0)
In acute myeloid leukemia patients CpG-methylation changes associate with resistance to induction chemotherapy. (2018) (0)
Contents Vol. 50, 2007 (2007) (0)
Im Fokus: Mammakarzinom (2006) (0)
Targeted Resequencing of MLL-PTD Positive AML Patients Reveals a High Prevalence of Co-Ocurring Mutations in Epigenetic Regulator Genes (2014) (0)
Changes in Bone Metabolism Induced by Short-Term Treatment with G-CSF for the Mobilization of Allogeneic Hematopoietic Progenitor Cells. (2005) (0)
Successful use of a double lumen port access in patients receiving dose reduced conditioning followed by allogeneic blood stem cell transplantation (2000) (0)
Effects Of Obstetric Factors On Weights And Cell Counts Of Cord Blood Units (2010) (0)
CD97 Expression in Acute Myeloid Leukemia Is Associated with FLT3-ITD Mutation Status (2014) (0)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT (2018) (0)
The Incidence of Central Nervous System Involvement in AML: A SAL-Tor Vergata Analysis (2011) (0)
PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE) (2019) (0)
Early Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk AML - Final Results From the Randomized AML 2003 Trial (2012) (0)
Session II: Nonmyeloablative stem cell transplantation and adoptive immunotherapy (2) (1999) (0)
[Perazine-induced agranulocytosis--case report and discussion]. (1985) (0)
Clofarabine-Based Salvage Therapy and Conditioning Regimen in Patients with Relapsed or Refractory AML (2013) (0)
[Feedback on service provision in cancer patients using the Ward Satisfaction Questionnaire (WSQ)--testing a new tool]. (2014) (0)
Das Gewebegesetz – ein „last-minute“-Gesetz? (2010) (0)
Mutations of cMYC Exon 2 Are a Rare but Recurrent Abnormality in Adult Patients with Acute Myeloid Leukemia (AML) (2015) (0)
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia (1986) (0)
Diagnosis and Treatment of Myeloproliferative Neoplasms in Germany: First Results from the SAL-MPN Registry (2014) (0)
Frequent GvHR-Like Syndromes Following Syngeneic Bone Marrow Transplantation Suggest Inappropriately Controlled Autoreactivity (1989) (0)
Nuclear Factor of Activated T Cells Regulates Down Syndrome Critical Region 1 Gene Expression in Megakaryocytes. (2006) (0)
[Severe hard tooth structure decay following full body radiotherapy prior to bone marrow transplantation]. (1990) (0)
107 MONITORING OF THERAPEUTIC RESPONSE TO LENALIDOMIDE IN DEL(5Q) MDS USING A RAPID 5-PARAMETER FLOW CYTOMETRIC DEL(5Q)-SCORE (2015) (0)
First experience of pentamidine-inhalation for prophylaxis of Pneumocystis carinii pneumonia after bone marrow transplantation. (1990) (0)
160-P: neXtype: A SAFE CAR ON THE NGS ROLLER COASTER (2013) (0)
Title Pages / Zur Situation klinischer Studien in Deutschland / Table of Contents (2013) (0)
Abstract 4232: More than a bridging therapy: Targeting CD123 with rapidly switchable universal CAR-T cells for treatment of acute leukemia (2020) (0)
Interleukin-10 Promoter Polymorphisms Associating with Severe Acute Graft-Versus-Host Disease In HLA-Identical Sibling Transplants. (2010) (0)
High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial (2017) (0)
Validation of a Molecular Risk Score for Prognosis of Patients with Acute Promyelocytic Leukemia (2016) (0)
C032 Is allogeneic hematopoietic cell transplantation a reasonable therapeutic option for elderly (>60 years) patients with de novo myelodysplastic syndromes? (2009) (0)
The Role of Expression of FLICE and FLICE-Inhibitory Protein Isoforms in Acute Myeloid Leukemia. (2005) (0)
Second Stem Cell Harvest from Unrelated Donors for Patients with Relapse or Graft Failure after First Transplantation: Patient Age >50 Years and Relapse of Malignant Disease Are Associated with Poor Outcome. (2006) (0)
Lymphocytopenia a s an Unfavorable Prognostic Factor in Patients With Cytomegalovirus Infection After Bone Marrow Transplantation (2003) (0)
Die Gesundheitswerkstatt des Schülerprojektes Be Smart Against Cancer – Ergebnisse einer telefonischen Befragung (2017) (0)
Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial (2010) (0)
Pharmakokinetische Untersuchungen bei zytostatischer Therapie : Kreibsleiden : Aktuelle Diagnostik und Therapie (1997) (0)
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
Besondere Behandlungs- und Betreuungsnotwendigkeiten bei jungen Krebspatienten: AYA-Workshop der DGHO, Berlin, Mrz 2011 (2011) (0)
Fachgesellschaft der Hämatologen und Onkologen fordert wirksamere Kontrollen und mehr Transparenz bei der Zubereitung von Zytostatika (2010) (0)
P115. Association between the EGFR-R497K polymorphism and overall survival in patients with advanced cancer of the head and neck receiving cetuximab based treatment (2011) (0)
Graft Versus Host Disease (GVHD) Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy – Results of the EVTAC Trial (2008) (0)
Multimodales Therapiekonzept für gastrale Marginalzonen B-Zell Lymphome vom MALT Typ im Stadium I und II1– aktueller Stand der HELYX Studie (2006) (0)
Im Fokus: Stammzelltransplantation (2007) (0)
Selective Expansion of Regulatory T-Cells during Lenalidomid Treatment of MDS with Isolated Deletion 5q (2014) (0)
NK-KIR Gene Repertoire and Outcome of Patients with Acute MyeloidLeukemia after Allogeneic Hematopoietic Cell Transplantation from UnrelatedDonors (2013) (0)
Comprehensive Risk Factor Analysis in 939 Adults with Acute Myeloid Leukemia Receiving Risk Stratified Post-Remission Therapy: Results of the Prospective Randomized AML96 Trial of the German Study Initiative Leukemia (DSIL). (2007) (0)
Handlungsbedarf Hautkrebsprävention in Kindetageseinrichtungen – am Beispiel Sachsen (2016) (0)
Dosisintensität und Zelltod (1999) (0)
Im Fokus - Dosisintensivierte bzw. dosisreduzierte Therapie (2005) (0)
Im Fokus: Individualisierte Supportivtherapie (2006) (0)
Rituximab-induzierte rapide Tumorlyse bei therapierefraktärer B-ALL: übersicht und Fallbericht (2002) (0)
Im Fokus - Stammzelltherapie (2005) (0)
Polymerase Chain Reaction for Detection of Various Aspergillus Species in Clinical Samples (1997) (0)
Krebsvorbeugung im Jugendalter – Die Effizienz eines Präventionsworkshops (2014) (0)
Im Fokus: Multiples Myelom (2008) (0)
Im Fokus: Weichteilsarkome (2006) (0)
Nachweis von Pathogenitätsfaktoren des Helicobacter pylori aus Paraffinschnitten von Patienten mit niedrigmalignem gastralem MALT-Lymphom und Korrelation mit klinischem Ansprechen nach Eradikationstherapie (2005) (0)
PROGAST-Studie: Prophylaxe der akuten intestinalen Graft-versus-Host-Disease nach allogener Stammzelltransplantation mittels Budesonid (2010) (0)
Häufigkeit, Klinik und Letalität der Pneumocystis carinii Pneumonien bei nicht-HIV-induzierter Immundefizienz (2011) (0)
Akute Leukämien (2017) (0)
Mitteilungen onkologischer Gesellschaften · Reports of Oncological Societies (2011) (0)
PS987 RIBOMETHYLOME CHANGES DEPEND ON DISTINCT PATTERNS OF C/D BOX SNORNAS IN AML SUBTPYES (2019) (0)
Sekundär hoch malignes MALT-Lymphom des Magens bei einem 69-jährigen Patienten mit gastrokolischer Fistel (2001) (0)
Stellungnahme der Lehrkräfte zur Tabakprävention an Berufsschulen – Beispiel Sachsen (2016) (0)
Posttraumatische Belastungsstörung (PTBS) nach Stammzelltransplantation – Häufigkeit und auslösende Faktoren (2009) (0)
Einschätzung von Visite und Stationsalltag bei Krebspatienten mit dem Stationsfragebogen (SFB) (2014) (0)
Fallserie: Behandlung von Patienten mit therapierefraktärem M. Crohn mit allogenen, adulten mesenchymalen Stromazellen (2011) (0)
Seltene Ursache einer hämorrhagischen Diathese (2008) (0)
Im Fokus: Maligne Lymphome (2010) (0)
New derivatives of thalidomide, its method of preparation and pharmaceutical compositions containing them. (1992) (0)
Im Fokus: Kopf- und Hals-Tumoren (2009) (0)
HELYX Studie Teil I/II: Zwischenergebnisse des multimodalen Therapiekonzeptes für gastrale Marginalzonen B-Zell Lymphome vom MALT Typ im Stadium I und II1 (2005) (0)
Selfinduction of cyclophosphamide and ifosfamide metabolism by repeated high dose treatment (2007) (0)
Im Fokus: Supportivtherapie (2011) (0)
Developing the CRISPR/Cas-system for Inactivation of Proto-oncogenes in Human Cancer Cells (2018) (0)
Erste Ergebnisse der HELYX Studie: Ein multimodales Therapiekonzept für niedrig maligne Non-Hodgkin-Lymphome des Magens vom MALT-Typ Stadium I/II1 (2015) (0)
Fortschritte in der Hämatologie und Onkologie (2012) (0)
Jahres-Inhalt, Vol. 13, 1990 (1990) (0)
‘Neue Therapieperspektiven mit Irinotecan bei gastrointestinalen Tumoren’ 3rd International Conference ‘Perspectives in Colorectal Cancer’ Dublin, 7.–9. Juni 2001 und Wissenschaftliches Symposium Post ASCO. Potsdam, 23.–24. Juni 2001 (2001) (0)
Integrative Onkologie - neues Design oder neues Denken?: Symposium im Rahmen der DGHO-Frhjahrstagung 2012, Berlin, Mrz 2012 (2012) (0)
Cyclophosphamide (CP) Pharmacokinetics and Metabolism After Repeated High Dose Administration in BMT (1985) (0)
Prophylactic fluconazole and Candida krusei infection. (1992) (0)
Myeloproliferative Erkrankungen — Polycythaemia vera, idiopathische Myelofibrose, essentielle Thrombozythämie (2006) (0)
Clinical pharmacology and metabolism of mitoxantrone (1986) (0)
8.14 Therapiestudien (2008) (0)
Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“ (2006) (0)
Die Laser Capture Mikrodissektion: moderne Analyse molekulargenetischer Alterationen (1999) (0)
Informationen für die Klinik / Clinical Information (1990) (0)
Infektionsprophylaxe mit i.v.-lmmunglobulinen in der Knochenmarktransplantation (1996) (0)
Zertifizierung in der Medizin: DGHO-Symposium, Berlin, Januar 2012 (2012) (0)
Im Fokus - Leukämien (2005) (0)
Im Fokus: Follikuläre Lymphome (2008) (0)
Diagnostik und Therapie derakuten myeloischen Leukämie (2009) (0)
Diagnostik der gastrointestinalen Graft-versus Host Disease mit Minisonden-basierter konfokaler Lasermikroskopie (2008) (0)
Prevention of viral infections after bone marrow transplantation (2005) (0)
Investigation ofPotential Interaction ofCiprofloxacin with Cyclosporine inBoneMarrowTransplant Recipients (1990) (0)
Akute gastrointestinale Graft-versus-Host-Disease nach allogener Stammzelltransplantation – eine retrospektive Analyse von klinischen, endoskopischen und histologischen Befunden (2006) (0)
[CT and HR-CT in the diagnosis of pulmonary complications of bone marrow transplantation]. (1994) (0)
Vorwort (2012) (0)
Erfolgreiche Behandlung eines therapierefraktären M. Crohn mit allogenen, adulten mesenchymalen Stammzellen – ein Fallbericht (2010) (0)
Erratum: Onkologe 5: 450–455 (1999) (2016) (0)
‘Erythropoietin’Besser leben! – Länger leben? Symposium und Podiumsdiskussion. 28. April 2001, Curiohaus, Hamburg (2001) (0)
Diagnostik der gastrointestinalen Graft-versus-Host Disease mit Minisonden-basierter konfokaler Lasermikroskopie (2007) (0)
Im Fokus: Tumorstammzellen (2009) (0)
New Aspects in the Pharmacokinetics and Metabolism of Mitoxantrone (1992) (0)
Informationen für die Klinik (1987) (0)
Im Fokus: Zielgerichtete Therapien - personalisierte Medizin (2012) (0)
Mitteilungen onkologischer Gesellschaften · Reports of Oncological Societies (2010) (0)
Sachwortverzeichnis/Subject Index 1990 (1990) (0)
Stellenwert der Transplantation hämatopoetischer Stammzellen in der Behandlung myelodysplastischer Syndrome (2001) (0)
ONKODIN: Onkologie, HÃ¤matologie - Daten und Informationen (2017) (0)
[Indications for chemotherapy in cancers of the esophagus, stomach and pancreas]. (2002) (0)
Detection and separation of the S-adenosylmethionine-decarboxylase inhibitor SAM486A in human plasma and urine by reversed-phase ion-pairing high-performance liquid chromatography. (2001) (0)
Pneumocystis-carinii-Prophylaxe nach Knochenmarktransplantation mit Pentamidin-Inhalationen (1991) (0)
Leukämien – Modellerkrankungen für Fortschritte in Diagnostik und Therapie (2006) (0)
Im Fokus - Lymphome (2005) (0)
Thalidomide derivatives, a process for their preparation and the use thereof in medicaments (1992) (0)
Pharmakokinetik von 5-Fluorouracil und Mitoxantron unter der isolierten Leberperfusion (1987) (0)
Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance (1991) (0)
Effektivere Behandlung der Peritonealkarzinose durch intraperitoneale Cis-Diamindichloroplatin (c-DDP)-Gabe mit systemischer Natriumthiosulfatprotektion (1986) (0)
Im Fokus - Urologische Tumoren (2005) (0)
Im Fokus: Rezidivtherapie (2005) (0)
Deutsche Osteoonkologische Gesellschaft gegründet (2010) (0)
Biochemische Grundlagen der zytostatischen Therapie (1982) (0)
Stammzelltransplantation mit Nabelschnurblut (2015) (0)
Im Fokus - Kolonkarzinom (2005) (0)
Im Fokus: Adjuvante Therapie (2009) (0)
Entwicklung eines Barrettkarzinoms auf dem Boden eines neu entstandenen Long-Segment-Barrettösophagus nach Radiochemotherapie eines primär gastralen, niedrigmalignen MALT Lymphoms Stadium IV – ein Fallbericht (2007) (0)
„Be smart against cancer“ – interaktiver Lehrfilm zur Krebsvorbeugung (2015) (0)
Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia (2014) (0)
Discontinuation of lenalidomide in patients with transfusion-dependent low- and intermediate-1 risk myelodysplastic syndromes with del(5q): sustained remissions, but not cure (2010) (0)
Identification Of Novel Markers Of Human AML Stem Cells Using High Resolution Proteomics and Transcriptomics (2013) (0)
Cancer: Education and Primary Prevention Starts in Childhood and Adolescence (2016) (0)
Patients’ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population (2013) (0)
Drug Resistance Testing of Acute Myelogenous Leukemia in Adults — Initial Results with the MTT Assay (1998) (0)
Loss of Heterozygosity Identified in Acute Myeloid Leukemia with Normal Karyotype Using SNP Microarrays. (2005) (0)
MYELOID NEOPLASIA Title: RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates Fasudil as an anti-leukemic drug Short shRNA screen in primary AML cells (2015) (0)
Band 24, Heft 4, August 2001 (2001) (0)
Gemtuzumab Ozogamicin (Mylotarg®) as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia. (2004) (0)
In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations (2014) (0)
reaction technique marrow transplantation as demonstrated by the polymerase chain Early occurrence of human cytomegalovirus infection after bone (2011) (0)
Original Research Report Large-Scale Immunomagnetic Selection of CD14 1 Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study (2003) (0)
Abstract B021: Treatment with a novel targeting module, redirecting UniCAR T cells against PSCA, delays subcutaneous tumor growth and prolongs survival of tumor-bearing NSG mice (2016) (0)
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) (0)
What Is the Outcome of Patients with Acute Leukemia Who Survive Severe Acute Graft-Versus-Host Disease? (2017) (0)
Aberrant Intracellular Retention of Mutated Receptor Tyrosine Kinase FLT3 in Human Leukemic Cells as a Potential Mechanism Supporting the Pathogenesis of Acute Myeloid Leukaemia. (2008) (0)
Pooled Data Analysis of Acute Myeloid Leukemia Patients <= 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup. (2005) (0)
S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA (2019) (0)
Specific Regulation of NFAT (Nuclear Factors of Activated T Cells) Expression in CD34+ Cells Differentiating into Diverse Hematopoietic Lineages. (2006) (0)
Poor Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for De Novo AML with Chromosome 7 Abnormalities: A Report for the ALWP of the European Group for Blood and Marrow Transplantation. (2007) (0)
Increased myelotoxicity of idarubicin: Is there a pharmacological basis? (2007) (0)
Im Fokus: Magenkarzinom (2010) (0)
High Expression of ENPP2/Autotaxin in Patients with FLT3-ITD Positive Acute Myeloid Leukemia. (2006) (0)
Inhibition of microRNA 10a, an Autophagy Modulator, Increases Chemosensitivity to Ara-C in Acute Myeloid Leukemia (2017) (0)
124-P : THE FUTURE HAS ARRIVED – ROUTINE HIGH THROUGHPUT HLA TYPING BY NGS (2013) (0)
Gfi136N As a Novel Marker and Therapeutic Target of MDS and AML (2014) (0)
Myelodysplastisches Syndrom (MDS) (2006) (0)
Subject Index Vol. 50, 2007 (2007) (0)
with acute myeloid leukemia ) is associated GFI1 ( Growth Factor Independence 1 A variant allele of (2010) (0)
Leptin is a contributing factor to the integrity of gastric mucosa (2000) (0)
Lenalidomide Modulates the Phenotype and Function of Human Mesenchymal Stromal Cells From Healthy Donors and MDS Patients. (2009) (0)
by allogeneic stem cell transplantation in patients with MDS or secondary in patients with (AML) following minimal conditioning after allogeneic peripheral blood stem cell transplantation in older patients: of reduced-intensity conditioning vs regimens and CD34+cell selection (2002) (0)
Effect of Intensive Chemo- and Radiotherapy Preceding Bone Marrow Transplantation on Lipid and Lipoprotein Metabolism (1992) (0)
Patients' perspective on palliative chemotherapy of colorectal and non-colorectal tumors. (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gerhard Ehninger?

Gerhard Ehninger is affiliated with the following schools:

Humboldt University of Berlin
University of Freiburg
University of Marburg
Ludwig Maximilian University of Munich
University of Nantes
Hannover Medical School
University of Hamburg
University of Tübingen
Technical University of Munich
University of Münster
Children's University
TU Dresden

Gerhard Ehninger's Academic­Influence.com Rankings

Why Is Gerhard Ehninger Influential?

Gerhard Ehninger's Published Works

Published Works

What Schools Are Affiliated With Gerhard Ehninger?

Gerhard Ehninger's AcademicInfluence.com Rankings